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Abstract 
Effective delivery of therapeutic agents to tumour cells is essential to the success of most cancer 
treatment therapies except for surgery. The transport of drug in solid tumour involves multiple 
biophysical and biochemical processes which are strongly dependent on the physicochemical 
properties of the drug and biological properties of the tumour. Owing to the complexities 
involved, mathematical models are playing an increasingly important role in identifying the 
factors leading to inadequate drug delivery to tumours. In this study, a computational model is 
developed which incorporates real tumour geometry reconstructed from magnetic resonance 
images, drug transport through the tumour vasculature and interstitial space, as well as drug 
uptake by tumour cells. The effectiveness of anticancer therapy is evaluated based on the 
percentage of survival tumour cells by directly solving the corresponding pharmacodynamics 
equation using predicted intracellular drug concentration.  
Computational simulations have been performed for the delivery of doxorubicin through various 
delivery modes, including bolus injection and continuous infusion of doxorubicin in free form, 
and thermo-sensitive liposome mediated doxorubicin delivery activated by high intensity focused 
ultrasound. Predicted results show that continuous infusion is far more effective than bolus 
injection in maintaining high levels of intracellular drug concentration, thereby increasing drug 
uptake by tumour cells. Moreover, multiple-administration is found to be more effective in 
improving the cytotoxic effect of drug compared to a single administration.  
The effect of heterogeneous distribution of microvasculature on drug transport in a realistic 
model of liver tumour is investigated, and the results indicate that although tumour interstitial 
fluid pressure is almost uniform, drug concentration is sensitive to the heterogeneous distribution 
of microvasculature within a tumour. Results from three prostate tumours of different sizes 
suggest a nonlinear relationship between transvascular transport of anticancer drugs and tumour 
size.  
Numerical simulations of thermo-sensitive liposome-mediated drug delivery coupled with high 
intensity focused ultrasound heating demonstrate the potential advantage of this novel drug 
delivery system for localised treatment while minimising drug concentration in normal tissue.  
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1.  Introduction 
 
Cancer is a major cause of mortality and morbidity in the developed and developing 
countries. Currently, cancer is treated primarily by surgery, radiation therapy and 
chemotherapy. Novel approaches, such as gene therapy, immunotherapy and 
antiangiogenesis therapy, have been developed extensively and are likely to become 
clinically available in the next few decades. Except for surgery, effective delivery of 
therapeutic agents to tumour cells is the key to success for these therapies. Therefore, 
in this thesis, the essential physical and biochemical processes involved in drug 
delivery to solid tumours are studied. This chapter presents the relevant background 
and preliminaries of the project. The objectives and strategies of the research are then 
defined, which is followed by an outline of the thesis. 
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1.1. Background 
1.1.1. Cancer 
Cancer is a set of diseases characterized by unregulated cell growth leading to invasion of 
surrounding tissues and spread to other parts of the body [1]. Cancer cells can divide and grow 
uncontrollably, forming malignant tumours and finally invading nearby normal tissues. Up to 
now, over 200 types of cancer have been discovered. As shown in Figure 1-1, the high mortality 
rate associated with cancer makes it one of the most serious life-threatening diseases in the world. 
Around 159,000 people died from cancer in the UK in 2011, indicating 252 deaths for every 
100,000 people.  
116.0+
99.6 – 116.0
89.7 – 99.6
73.3 – 89.7
<73.3
No Data
Death per 100,000
Population*
*All cancers except non-melanoma skin cancer  
Figure 1-1. World cancer death 2012 
The causes of cancer are diverse, complex and not totally understood [2]. Various factors have 
been suggested to increase the risk of cancer, including pollution, radiation, industrial products 
and certain types of infections caused by damaged genes or combined with existing genetic faults 
within cells. Cancerous mutations of proliferation related genes, proto-oncogenes and/or tumour 
suppressor genes, drive cancer cells to go on duplicating themselves.  
Cancer seems to develop progressively [2]. As cancer cells expand, the original space becomes 
insufficient for their uncontrolled growth, resulting in invasion of increasing number of cells to 
the adjacent normal tissues. In order to acquire oxygen and nutrition to support cancer growth, 
normal cells are signalled to help develop new blood vessels. These vessels tend to be leaky and 
with abnormal geometric properties, which are different from blood vessels in normal tissues. In 
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addition, cancer cells can migrate from the primary cancer and spread to more distant parts of the 
body through the blood stream or lymphatic system to establish new colonies of cancer cells. 
These new settlements, termed metastases, are the major cause of death since vital organs can be 
damaged by cancer cells [1]. Ideally, treatments should start before cancer cells invade into other 
organs.  
1.1.2. Anticancer Therapy  
Various anticancer treatments are available in clinics, and the choice of these treatments is 
strongly dependent on the location, growth stage of cancer as well as the health condition of 
patients, etc. The main anticancer therapies are outlined below. 
(1) Surgery 
Surgery is cutting away tissue from patient’s body. Given that it is a local treatment, surgery may 
cure a localised cancer that is totally contained in one area before metastases taking place. In 
surgery, tumour and some of its surrounding normal tissues are removed to make the margin 
clear. Considering that cancer may invade the lymphatic system, the nearest lymph nodes are 
also removed. This is a preferred treatment for cancer, and can offer a complete cure in some 
cases [1]. 
After spreading of cancer cells, surgery usually cannot cure the cancer, but may also help 
patients live longer and reduce/control pain. Another application of surgery is to prevent or 
reduce the risk of cancer. People at a high risk of a particular type of cancer (e.g. bowel or breast 
cancer) may choose surgery to remove the relevant tissue. 
Surgery is limited by the type of cancer. Certain types of cancer are difficult to be removed due 
to their location, and insufficient removal may result in regrowth of cancer. On the other hand, 
spalling of cancer cells during surgery may cause the spread of cancer cells.   
(2) Chemotherapy 
Chemotherapy is the use of cytotoxic or cytostatic drugs that respectively kill malignant cells or 
prevent them from proliferating. The effectiveness of chemotherapy strongly depends on the 
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amount of drugs accumulated in the tumour, exposure duration to drugs and the proportion of 
cell population that is proliferating. 
There are more than 100 different anticancer drugs currently available and new drugs are being 
developed all the time. The choice of drugs is highly related to the type and stage of tumour. 
Chemotherapy kills tumour cells by damaging the genes that make cells divide, or it may 
interrupt the chemical process involved in cell division. The process affected by normal 
chemotherapy drugs are summarized in Table 1-1.           
Table 1-1. Processes affected by chemotherapeutic drugs [1] 
Drug Process Affected Cancer Treated 
Cisplatin DNA synthesis Ovary, Testis 
Methotrexate Dihydrofolate reductase Breast, Placenta 
5-Fluorouracil Thymidylate synthase, RNA synthesis Stomach, Breast, Colorectal 
Doxorubicin DNA & RNA synthesis Lung, Breast, Leukaemia 
Vincristine Tubulin polymerisation Lymphoma, Testis 
Chemotherapy is a systemic treatment. Drugs are circulated around the body in the bloodstream 
and can reach cells almost anywhere. Without specifying the target, normal cells can also be 
killed and hence the normal function of tissue can be compromised. This is known as side effects, 
which can seriously offset the treatment outcome. Side effects vary according to the drug, but 
there are some most common side effects, as shown in Table 1-2. 
Table 1-2. Common side effects caused by chemotherapeutic drugs [1] 
Drug Side Effects 
Cisplatin Nephrotoxicity, Ototoxicity, etc 
Methotrexate Myelosuppression, Alopecia, Dermatitis, etc 
5-Fluorouracil Myelosuppression, Cardiac toxicity, etc 
Doxorubicin Cardiomyopathy, Myelosuppression, Leukopenia, etc 
Vincristine Chemotherapy-induced peripheral neuropathy, Hyponatremia, etc  
During chemotherapy, drugs often stop the bone marrow from generating enough blood cells. 
Without adequate white blood cells, risks of developing infections will increase, which low 
levels of red blood cells result in the shortage of nutrition and oxygen supply, causing 
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breathlessness and tiredness. Most drugs cause hair loss, but this effect is temporary and hair 
starts to grow back a few weeks after chemotherapy ends.  
Changes in the way that liver, kidney, lung and heart work can also be caused by chemotherapy 
drugs. These changes are usually temporary, but can be permanent for some patients. 
Doxorubicin is a typical anticancer drug, and its most serious side effect is cardiomyopathy, 
which can lead to heart failure. In order to minimise the risk for this, the total dose of 
doxorubicin in a life cycle is limited to 550 mg per unit body surface area [3]. 
(3) Radiotherapy 
Radiation is applied to kill malignant tumour cells by causing irreversible damages to DNA 
within cancer cells. Since tumour stem cells are not as sensitive as cycling cells to radiation, the 
entire treatment process may last longer than other types of treatment. According to the way 
radiation is used, basically there are two types of radiotherapy: external radiotherapy and internal 
radiotherapy. 
In external radiotherapy, a narrow radiation beam with high intensity is generated to a well 
identified area of the patient’s body. X-ray and gamma ray are the most common radiation used 
clinically. Since radiation can pass through the body, superficial and deep-seated tumours can be 
treated without surgical trauma. Given that the treated area is well identified before radiotherapy, 
damage to adjacent and overlying normal cells can be minimized by re-directing the radiation 
beam to restrict the radiation dose only being focused in tumour.  
In internal radiotherapy, radioactive implants are inserted within or close to the target tumour, 
and a radioactive liquid is administrated orally or injected first, which is then transported by the 
circulation system. The radioactive component of the liquid is called isotope, which is designed 
to attach to a 'bioconjugate' molecule, such as an antibody, to cause the liquid to be taken up by 
tumour cells.  
Although radiotherapy is a local treatment, some normal cells are inevitably killed, resulting in 
undesirable side effects. During the treatment, tiredness is a common side effect since healthy 
cells need to be repaired or the level of blood cells drops. In addition, radiotherapy can also 
cause side effects in particular organs, such as in the head, neck or chest.   
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(4) Novel and Emerging Therapies 
High intensity focused ultrasound (HIFU) is a novel and fast developing therapy [4]. High 
frequency ultrasound waves are emitted from an ultrasound transducer, and the waves deliver a 
strong beam to the targeted region in order to elevate the temperature to kill tumour cells. It is a 
highly targeted and localised treatment. Because of the non-invasive nature of the sound wave 
used, the associated side effect is less than the other treatment methods. Patients may feel 
localised pain in the first 3~4 days. 
Photodynamic therapy (PDT) is usually used to treat non-melanoma skin cancer [5]. Drugs 
(known as photosensitiser) are firstly administrated to add a specific type of light sensitivity to 
tumour cells, which are then killed by exposure to this light. However, PDT can make skin and 
eyes sensitive to light, and may cause death of nearby normal cells.  
Gene therapy involves inserting specific genes into malignant or normal cells in order to modify 
their gene expressions. Either viral or non-viral agents can be used to deliver the specific genes, 
and viral must be attenuated before used. This therapy is with high specificity, but is still in 
development stage. A number of early stage clinical trials have been carried out [6-8].  
Clinically, the treatment methods are strongly dependent on the type, location and growth stage 
of tumour as well as the health condition of patient. Usually, various treatments are combined in 
order to improve the overall treatment outcome. Most of these therapies depend on effective 
delivery of therapeutic agents to the targeted tumour.  
1.1.3. Thermo-Sensitive Liposome-Mediated Drug Delivery 
For an effective delivery, adequate therapeutic agents should reach the tumour while drug 
accumulation in normal tissues needs to be prevented or reduced in order to minimize side 
effects. Since most therapeutic agents are carried by systemic bloodstream to the entire body, 
their usages are hence limited. As an improvement, thermo-sensitive liposome-mediated drug 
delivery has been developed to overcome this shortcoming.  
Anticancer drugs are encapsulated by thermo-sensitive liposomal particles which are 
administrated into the blood stream as usual [9]. Ideally, these particles should retain their load at 
body temperature, and rapidly release the encapsulated drugs within a locally heated tumour 
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region. The fast release is due to liposome thermo-responsiveness, which arises from a phase 
transition of the constituent lipids and the associated conformational variations in the lipid 
bilayers [10-12].  
Localised heating can be achieved by various means, including: microwave, radiofrequency 
electric current, laser, and HIFU transducer [13]. The sound wave generated by HIFU transducer 
is a mature technology which has been adopted in HIFU treatment alone without the use of drugs, 
and is found to have very few side effects.  
1.2. Objectives of the Study 
The delivery of anticancer drugs consists of multiple processes, as the drugs must make their 
way into the blood vessels of the tumour, pass through the vessel wall to enter the interstitial 
space and be taken up by tumour cells. On the one hand, these processes are dependent on the 
physicochemical properties of the drugs, such as diffusivity and drug binding to cellular 
macromolecules. On the other hand, the biological properties of a tumour, including tumour 
vasculature, extracellular matrix components, interstitial fluid pressure, tumour cell density and 
tissue structure and composition, also serve as determinants in these processes. Unfortunately, 
the structure and morphology of microvessels in malignant tumours is highly abnormal and 
heterogeneous, which create a great barrier for effective delivery of drugs to cancer cells. 
The overall aim of this project is to develop a multi-physics model for the simulation of transport 
processes of therapeutic agents in solid tumours. The main focus of this project is on the 
development of transport models for free drug and drug loaded thermal-sensitive liposomes, with 
the following specific objectives: 
(1) To develop a mathematical model for the transport of anticancer drugs in their free form;  
(2) To determine the optimal administration mode and schedule for maximum accumulation of 
drugs in tumour cells; 
(3) To develop a mathematical model for the transport of drug-loaded thermosensitive liposomes; 
(4) To fulfil objective (3), a bioheat transfer model with HIFU heating needs to be developed; 
(5) To examine the effect of different drug delivery modes on drug distribution in solid tumours.  
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A research strategy has been developed in order to accomplish these objectives. The 
mathematical models are applied to realistic tumour models reconstructed from magnetic 
resonance images (MRI). In the basic tumour models, a uniform microvasculature is assumed. 
This assumption is subsequently relaxed by incorporating microvasculature heterogeneity 
derived from in vivo MRI data, and the effect of microvasculature distribution on drug 
concentration in tumour is investigated. Finally, the drug delivery model is coupled with the 
bioheat transfer model under HIFU heating in order to study thermal-sensitive liposome-
mediated drug delivery.   
1.3. Structure of This Thesis 
This thesis includes seven chapters, which are organized in a logical sequence. In Chapter 2, a 
comprehensive survey of literature is given for the research to cover tumour properties, drug 
delivery modes and drug transport processes. In Chapter 3, mathematical models utilized to 
achieve the objectives and their implementations are described. Chapters 4, 5 and 6 present the 
findings and analysis of results of drug transport process and treatment efficacy with various 
administration modes and biological properties. Chapter 4 compares the bolus injection and 
continuous infusion, and Chapter 5 investigates the influence of heterogeneous vasculature and 
the size of tumour. Chapter 6 focuses on drug transport under thermal-sensitive liposome-
mediated drug delivery. Finally, conclusions and suggestions for future work are outlined in 
Chapter 7.  
 
  
 
 
 
 
 
 
 
 
 
 
2.  Literature Review 
 
In this chapter, a comprehensive review of the literature on topics related to drug 
transport in solid tumour is given. Firstly, the unique characteristics of solid tumour 
are described, which serves as an introduction to the microenvironment in tumour. 
This is followed by a review of previous studies of drug delivery modes, covering 
both medical and mathematical modelling aspects. Finally, the key processes 
involved in drug delivery to solid tumour are summarized. 
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2.1. Characteristics of Solid Tumour 
Different from normal tissues, solid tumours have abnormal characteristics that may strongly 
influence the transport of anticancer drugs to and within tumours.  
2.1.1. Tumour Vasculature 
Microcirculation plays an important role in the delivery of anticancer agents to solid tumours 
[14-16]. Small tumours with a diameter less than 2 mm are perfused by blood from their host 
normal tissues [17]. With the growth of a tumour, new blood vessels are formed either through 
recruitment from pre-existing network of the host tissue or resulting from the angiogenic 
response of tumours [18, 19]. Both morphological features and functions of tumour vasculature 
differ from those in normal tissues. 
 
Figure 2-1. Normal and tumor vasculature.  
A) Normal vasculature: vessels are aligned in a well-organized manner; B) Tumor vasculature: vessels are dilated 
with non-uniform diameters and random branching patterns (extracted from [20]) 
Tumour vasculature becomes tortuous, elongated, and often dilated as a result of tumour growth 
(Figure 2-1). The morphological structure of vessels can also change in the growing process of a 
tumour, with some features that are rarely present in normal tissues. As shown in Figure 2-2, 
trifurcation is a typical pattern which is frequently seen in tumour vasculature. Loops can be 
found in both arterial and venous trees in tumours, and there are two types: self-loop and true 
loop [21]. Self-loops are planar loops consisting of only two vessels without any other side 
branches, whereas true loops are non-planar composed of several vessel segments with many 
branches. Polygonal structure exists in the tumour capillary meshwork. Venous convolution is 
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often observed in close proximity to the feeding/draining vessels. The result of this kind of 
vascular architecture may lead to plasma skimming and heterogeneous vessel haematocrit levels.  
 
Figure 2-2. Typical architecture of blood vessels in solid tumour (extracted from [21] )  
Including (1) trifurcations, (2) self-loop, (3) characteristic polygonal structure of the capillary meshwork, (4) venous 
convolutions, and (5) small (20~40 µm) vessels branching off of large (200 µm) vessels 
The diameters of arterioles and venules decrease monotonically as branching order increases. 
Comparisons presented in Table 2-1 [21-24] show that blood vessels in tumour have a large 
diameter, which may exceed the size of anticancer agents (<1~2 µm for free drugs and 100 nm 
for liposome particles [25, 26]). Comparisons between unit volume of tumour and normal tissue 
show that the length, surface area and fraction of vasculature volume are significantly larger in 
tumours.  
Table 2-1. Morphological features of tumour microvasculature 
 
Diameter (µm) Length Surface Area Vascular Volume 
Fraction (%) Capillary Venules (cm/mm
3
) (mm
2
/mm
3
) 
In Tumour 5~20 15~70 36 70 50 
In Normal Tissue 5~8 12~50 160 20 20 
One of the unique characteristics of tumour vasculature is its high leakiness. The abnormal 
structure of vessel wall in tumours [27-29] may be one of the reasons. Large inter-endothelial 
junctions, increased numbers of fenestrations, vesicles and vesico-vacuolar channels, and a lack 
of normal basement membrane are often found in tumour vessels [30, 31]. Perivascular cells 
have abnormal morphology and heterogeneous association with tumour vessels. In 
correspondence to these structural alterations in the tumour vessel wall, the cut-off size of pores 
on tumour microvasculature is in the range of 100~780 nm, varying according to the location and 
growth stage of the tumour [26, 32, 33]. Compared to the pore size of 2~6 nm in most normal 
2. LITERATURE REVIEW 
28 
 
tissues [34-36] and 40~150 nm in kidney, liver and spleen [37, 38], tumour vasculature with 
large pores is favourable for anticancer drugs to pass through, and thereby easing the drug 
delivery process.  
The distribution of tumour vasculature depends strongly on the location and growth stage of the 
tumour. In theory, four regions can be categorized based on the type and function of tumour 
vasculature [39]: (1) necrotic region with no functional vasculature; (2) semi-necrotic regions 
with capillary, pre- and post-capillary extended; (3) stabilized microcirculation region 
characterised mainly by venules, veins and a few arterioles; and (4) tumour advance front with 
arterioles, capillaries and venules. Jain simplified this region-categorization as necrotic region, 
semi-necrotic region and well-vascularised region along the radial distance [40], as shown in 
Figure 2-3. 
Necrotic
Region
Semi-
Necrotic
Region
Well
Vascularized
Region  
Figure 2-3. Regions in Solid Tumour (extracted from [40] ) 
In reality, two types of vascular structure can be observed from in vivo images [41]. In tumours 
with peripheral vascularisation, the centre is poorly perfused and vessels are located mainly in 
the periphery. These may also occur in fully grown tumours that have already invaded into 
normal tissues. In tumours with central vascularisation, vessels proliferate from the centre and 
form a tree-like structure. In this case, vessel volume in the centre is higher than that in the 
periphery of the tumour. 
2.1.2. Blood Flow Rate 
Given that anticancer agents are carried by the blood stream to the target solid tumour, tumour 
blood flow rate may greatly influence the transport of drugs. Under the assumption of steady and 
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fully developed flow and ignoring geometric complexities, the volumetric flow rate in a tumour 
vascular network is proportional to the pressure difference between its arterial and venous ends, 
and inversely proportional to blood viscosity and geometric resistance [42].  
Microvasculature pressure at the arterial ends is found to be similar in both tumour and normal 
tissue [43], but pressure in the venular side is significantly lower in a tumour when compared to 
normal tissue [17]. Because most blood vessels in tumours are veins whilst arteries mainly exist 
in tumour advance front region [41], the driving force for blood flow is greater at the periphery. 
This is one possible reason for the heterogeneous distribution of blood flow in tumour [39, 44]. 
Viscous resistance depends on plasma viscosity and parameters describing the number, size and 
rigidity of red blood cells, while geometric resistance is directly associated with the 
morphological features of microvessels, such as the number of vessels, branching patterns, 
diameter and length [42]. Both of these resistances may be altered by changes in environmental 
or internal conditions. Compared to normal tissue, greater resistance is found in tumours owing 
to the drainage force from the tumour cells and proteins existing in the extracellular space, as 
well as the large vessel diameter and long vessel length. 
Table 2-2. Mean blood flow rate in human tumour and normal tissue (ml/g/min) [45]. 
 Brain Lymphatic Breast Uterus Liver 
Tumour
 
0.50 0.45 0.23 0.33 0.12 
Normal Tissue 0.57 0.40 0.83 0.13 1.05 
A number of studies of blood flow in human tumours and their holding tissues have concluded 
that there is a wide range of variations in blood flow rate even for the same type of tumour [45]. 
Comparisons summarized in Table 2-2 show that the difference in mean blood flow rate between 
tumours and normal tissues depend strongly on their location.  
2.1.3. Lymphatic Drainage  
The lymphatic system is a part of the circulatory system spreading into many organs. Lymphatic 
vessels are structurally similar to capillaries, with a wall formed by a single layer of endothelial 
cells [46]. However, the lymphatic wall is more permeable than the capillary wall and is not size-
selective [17]. Its main function is to return interstitial fluid back to the blood stream partly due 
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to the low pressure in lymphatics, and to clear extracellular matrix deposits, such as proteins, 
from the interstitial space in most normal tissues [47]. The diameter of lymphatic vessels in 
tissue is around 40 μm, and the velocity is in the range of 1.4~20 μm/s, with an average value of 
8 μm/s [46]. Hence, drugs can be constantly cleared in regions with a high density of functional 
lymphatic vessels.  
2.1.4. Interstitial Fluid Pressure 
The interstitial space of a tumour is complex partly due to the extracellular matrix and non-
uniform vasculature distribution [46]. The pressure in a tumour can exceed atmospheric by 
greater than 4200 Pa [46, 48]. This high pressure can be attributed to: (1) insufficient normal 
removal of interstitial fluid due to lack of lymphatics; (2) high permeability of tumour 
vasculature, and (3) vascular collapse caused by cell proliferation in a confined volume [15].  
Models of microenvironment as complex as interstitial space of a tissue require a proper 
description of its microstructure. The organization of capillaries in tumours is random owing to 
the abnormal morphological features, and the inter-capillary distance is usually 2~3 orders of 
magnitude smaller than the length scale for drug transport [49], hence a useful model can be 
based on percolation description of porous media governed by Darcy’s law [46].  
A theoretical platform has been set by Baxter and Jain [49] for transvascular exchange and 
extravascular transport of fluid and macromolecules in tumour based on Darcy’s law describing 
the interstitial space as a porous media. Validated by experimental data, their simulations of 
tumour microenvironments in both tissue-isolated and subcutaneous tumours indicate that 
interstitial fluid pressure in a tumour is higher than in normal tissue with a uniform distribution 
in the centre even if in the presence of a necrotic core, and there is a sharp drop of interstitial 
pressure at the periphery of the tumour [49-51].  
2.2. Modes of Drug Delivery to Solid Tumour 
The route and method of drug administrated affect the kinetics of bio-distribution and 
elimination, therefore, the effectiveness of chemotherapy [46]. Modern pharmaceutical science 
provides many options for drug administration to meet specific requirements in clinical 
anticancer treatments. 
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2.2.1. Traditional Administration 
Anticancer drug administration traditionally includes oral delivery and intravenous injection. 
Because eating is one of the most common acts in daily life, oral intake is always preferred. It is 
painless, uncomplicated and self-administrated [46]. However, due to the fact that many drugs 
are degraded within the gastrointestinal tract, or cannot be sufficiently absorbed, the treatment 
efficacy is seriously compromised.    
Drug delivered by intravenous infusion is therefore adopted to offer a more rapid and efficient 
therapeutic outcome. With this administration method, nearly 100% of the drug is bioavailable 
and the plasma concentration level can also be controlled continuously [46]. The disadvantages, 
such as risk of overdose and infection, can also be avoided. Nowadays, intravenous injection is 
the most common administration mode in anticancer treatment.   
Studies on infusion duration were attempted with an aim to maximise intracellular drug 
concentration and reduce side effects. Noticing that high plasma concentration of doxorubicin 
may cause serious cardiotoxicity [3, 52], Legha [53] prolonged the infusion duration to 48 hours 
or 96 hours in treatments for 21 patients, while the other 30 control patients received standard 
intravenous injection with the same clinical dose. It was found that plasma levels of doxorubicin 
were reduced by continuous infusion, thereby reducing the risk of cardiotoxicity. Comparison 
also showed that the anticancer efficacy was not compromised. 
Similar clinical studies were carried out by Hortobagyi [54]. The initial group of breast cancer 
patients were treated by doxorubicin with bolus injection while in the other group doxorubicin 
was administrated via a central venous catheter over a 48-hour or 96-hour continuous infusion 
schedule. Anticancer treatment outcomes revealed that there were no differences between these 
two groups, but continuous infusion was less cardiotoxic than bolus injection. 
El-Kareh and Secomb [55] suggested that shorter infusion duration might improve treatment 
efficacy, and explored it by numerical studies. The anticancer efficacy is reflected by survival 
cell fraction based on the predicted peak intracellular concentration over the entire treatment 
period. Comparison between bolus injection and continuous infusion of 50, 100, 150 and 200 
minutes indicated that infusion duration had a strong influence on the predicted outcome. An 
optimal duration for continuous infusion was found to be within 1 to 3 hours.  
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2.2.2. Nanoparticle-Mediated Delivery 
In order to reduce the risk of side effects caused by high drug concentration in normal tissues, 
cytotoxic drugs are encapsulated in nanoparticles, typically liposomes, before being 
intravenously administrated into blood stream [56, 57]. The term “liposome” was firstly 
introduced to describe one or more concentric lipid bilayers enclosing an equal number of 
aqueous media which can be entrapped in the core during formation [46, 58]. Usually, liposomes 
are designed to be in the range of 70 to 200 nm in diameter in order to increase its circulation 
time in the blood stream [59]. Decreasing the diameter of liposome to less than 70 nm would 
result in 70% of the injected dose being accumulated in liver, while larger liposomal particles 
with a diameter greater than 200 nm are more likely to be taken up by the spleen, resulting in a 
reduced level in blood [60].  
Because of phagocytosis by cells of the reticuloendothelial system, liposomes disappear rapidly 
in the blood stream [46]. Hence, modifications on the liposome structure are required. 
Polyethylene Glycol (PEG) is now widely adopted as an important component in liposomal layer 
in order to prolong the circulation of liposomal nanoparticles in the blood stream. The drug 
concentration, therefore, can be maintained at a sufficient high level for effective cell killing [56, 
61]. The pharmacokinetics of liposome-mediated doxorubicin in cancer patients was 
qualitatively analysed by comparing with the same dose of doxorubicin delivered in free form 
[62].  Results have shown clearly that liposome-mediated delivery can reduce plasma clearance 
and increase doxorubicin concentration within tumours. Plasma elimination of doxorubicin-
loaded liposomes follows a bi-exponential decay function with half-lives of 2 and 45 hours [62].  
In vivo experiments on human prostate carcinoma, which is implanted subcutaneously into nude 
Swiss mice, demonstrated that liposome-encapsulated doxorubicin could enhance the therapeutic 
efficacy owing to reduced systemic elimination, increase penetration in tumour and prolong 
liposome presence with slow drug release [63]. To assess the clinical benefit of liposome-
encapsulated doxorubicin, 297 patients with metastatic breast cancer with no prior chemotherapy 
were randomized to receive 60 mg/m
2
 liposome-encapsulated doxorubicin or conventional 
doxorubicin in combination with 600 mg/m
2
 of cyclophosphamide until disease progression or 
unacceptable toxicity was reached [64]. Results showed that liposome-encapsulated doxorubicin 
could significantly reduce cardiotoxicity and improve the therapeutic effectiveness.  
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Controlled release is important in making chemotherapy a localised treatment. With a thermo-
sensitive liposomal membrane, in theory, no drug can be released until it is heated beyond its 
phase transition temperature [65].  A large number of experimental studies have been carried out 
to meet this goal. Thermo-sensitive liposomes sterically stabilized in human plasma have been 
developed by Gaber [66], while Unezkazi [67] and Lindner [68] developed improved 
formulations to offer both prolonged circulation and thermo-sensitivity. Optimization study on 
liposome particle was carried out by Tagami [69] to reduce the release rate at body temperature 
while maximising the release rate at mild hyperthermia.   
Fast temperature elevation can be obtained by laser, microwaves, radiofrequency electric current 
[13] and high intensity focus ultrasound (HIFU) [70]. Ultrasound has been used clinically to 
apply thermal therapy non-invasively at targets that are unavailable to other heating methods 
[71]. Staruch tested localised drug release with HIFU heating by in vivo experiments on rabbits 
[72, 73]. In their experiments, a HIFU beam was scanned in a circular trajectory to heat a given 
region in normal thigh [72] and tumour [73] to 43
o
C lasting for 20~30 minutes. Localised 
heating is controlled by MRI thermometry. Encapsulated doxorubicin with thermo-sensitive 
liposome was intravenously administrated during hyperthermia. Comparison between heated and 
unheated regions indicated that MRI-controlled HIFU hyperthermia could enhance local drug 
delivery.   
Temperature elevation in a liver tumour was predicated by numerical studies in Sheu’s work [74]. 
Based on a patient-specific liver model, the large hepatic artery was modelled explicitly to 
investigate the impact of blood flow on temperature elevation. However, neither the real 
geometry of hepatic tumour nor drug release was included in this study.  
Researchers also investigated HIFU heating modes in order to achieve a homogeneous 
temperature profile in tumour. Based on a 2-D idealized circular model, variables in fast 
scanning method with a short sonication duration for HIFU treatment were examined [75]. 
Results showed that fast scanning method could produce a planned lesion regardless of its 
scanning path. The final temperature profiles were highly dependent on the applied power and 
tissue perfusion. Theoretical and experimental studies [76, 77] suggested that signal point fixed-
gain proportional-integral control coupled with multiple heating points along a rapid scanned 
trajectory could result in a homogeneous temperature profile in a given region. 
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2.2.3. Polymer Implant 
Apart from nanoparticle-mediated delivery, a polymer implant is another delivery method 
developed to overcome the lack of targeting in common methods. The anticancer drug is firstly 
dissolved in polymers, and then the drug needs to diffuse through the polymer after being 
implanted and finally dissolve into the extracellular space of tumour. A number of polymeric 
materials have now been approved for clinical use. The most extensive type is non-degradable 
hydrophobic polymers. The development of biodegradable polymers with the advantage that no 
residual material remains in the tissue has enabled more anticancer agents with low diffusivity  
to be delivered to solid tumours [46]. However the design of these polymers is complex since 
large quantities of potentially harmful products may be released in the body.  
Wang [78] showed that implanting IgG-loaded polymer in the cavity left after surgical removal 
of a tumour may improve the anticancer efficacy. However, Teo [79] found that surgical removal 
of the tumour alone could only enhance drug delivery in bis-chloroethylnitrosourea (BCNU) 
treatment in limited time. Intratumoural administration with optimization is capable to improve 
treatment efficacy and reduce drug concentration in normal tissue [80, 81]. 
2.3. Drug Transport in Solid Tumour 
Systemic administration is the main delivery method for chemotherapeutic agents. Following its 
administration into the blood stream, anticancer drug experiences sequential processes before 
reaching the targeted tumour cells. These processes (shown in Figure 2-4) are described in detail 
below.   
Protein
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Figure 2-4. Schematic diagram of drug transport 
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2.3.1. Transport within Blood Vessel 
After administration, therapeutic agents begin to circulate in the systemic circulation to all over 
the body. Drug transport within blood stream is determined by drug properties and the in vivo 
environment. Drugs that are transported via the blood may disperse into tissue when passing by. 
In addition, kidney and other organs can eliminate drugs from the circulation system by filtering 
plasma continuously, and thereby compromising the treatment effect. This function of renal 
excretion is known as plasma clearance, which may vary according to the drug type [82-84].  
Rapid Peripheral 
Compartment (V2)
Central 
Compartment  
(V1)
Slow Peripheral 
Compartment (V3)
I(t)
 
Figure 2-5. Schematic diagram of three-compartment model 
Pharmacokinetics is classically represented by compartment models describing drug plasma 
concentration as a function of time, I(t). A human body can be represented as three 
compartments with the volume distribution at steady state shown in Figure 2-5: the central 
compartment (V1) for blood plasma, rapid (V2) and slow (V3) peripheral compartments 
corresponding to dense and sparse vessel volumes, respectively. Drugs in the central 
compartment can be cleared out, and there are two-way exchanges between the central and 
peripheral compartments, as shown in Figure 2-5.  A two-compartment model has also been 
adopted in mathematical modelling of the delivery of anticancer agents, which consists of a 
central compartment and periphery compartment, with inter-compartmental exchange taking 
place in both directions.  
Plasma concentration is associated with plasma clearance, dosage and administration mode. The 
pharmacokinetics of doxorubicin has been evaluated in the plasma of 12 breast cancer patients 
receiving no prior treatment [85]. Drug concentration was obtained by testing plasma samples 
collected at various times after administration. The successive half-lives were 0.08 hour, 0.822 
hour and 18.9 hour, indicating that a three-component exponential function would be better 
suited for doxorubicin concentration in blood plasma. 
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In addition to red blood cells, white blood cells and platelets, blood also contains a range of 
proteins. Extensive bindings between these proteins and drugs have been observed in clinical and 
experimental conditions. Plasma pharmacokinetics of doxorubicin with a 15 minutes continuous 
infusion were studied in 10 breast cancer patients [86]. By applying high performance liquid 
chromatography, Green found that 75±2.7% of the total plasma concentration of doxorubicin 
was bound with protein over the whole range of observed concentrations. This high rate of 
binding can effectively reduce the plasma concentration of free doxorubicin and affect the 
amount of drug reaching tumour cells. On the other hand, the retention of drug in blood can be 
extended because of the low plasma clearance rate of protein [17].  
2.3.2. Transport through Blood Vessels 
Being transported within the circulatory system, some drugs can be extravasated to the interstitial 
space owing to the high permeability of tumour vasculature. Drug transport through the 
vasculature wall depends on convection and diffusion.  
Drug transport by convection is associated with fluid flux across the vessel wall. This fluid 
movement is determined by hydrostatic and osmotic pressure difference between the lumen and 
interstitium. Drug transport by diffusion is driven by the concentration gradient between blood 
and interstitial fluid, and is also related to the permeability and area of blood vessels for drug 
exchange. This implies that drug can also be transported back to blood when the gradient 
reverses. Although drugs can be carried by endothelial cells, transcytosis has been found to play 
a minor role when compared with convection and diffusion [17].  
The pore model is widely adopted in numerical study of drug transport through blood vessels. 
Deen [87] reviewed studies of the hindered transport through pores on membrane that were 
aimed at predicting applicable transport coefficients from fundamental information, such as the 
size, shape and electrical charge of the solutes and pores in liquid-filled pores. The pioneering 
work on drug transport in solid tumour was conducted by Baxter and Jain. Employing the pore 
model described in Deen’s work [87], they developed a general mathematical platform for trans-
vascular and interstitial transport of fluid and macromolecules [49, 50, 88, 89]. 
Through application to an idealized tumour core model, Eikenberry [90] investigated the 
delivery of soluble doxorubicin from a capillary to its surrounding tumour mass to examine the 
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penetration of doxorubicin under different dosage regimens and microenvironment in solid 
tumour. Drug infusion duration was found to be an important factor in determining the spatial 
profile of tumour cell killing, and extending the infusion duration or fractionating the dose would 
help improve the treatment effect. Numerical results showed that only a limited amount of 
doxorubicin could be delivered into solid tumours.  
The application of a pore model was extended by El-Kareh and Secomb [55] to study liposome-
mediated delivery of doxorubicin to solid tumours. A mathematical model was developed and 
applied to compare the performance of various administration modes of both free form and 
liposomal encapsulated doxorubicin. The treatment outcome was predicated based on peak 
intracellular concentration without considering the dynamics of tumour cell density. Their 
simulation results indicated that continuous infusion with an optimal infusion duration yielded 
the best treatment efficacy, and there was a clear advantage of thermo-sensitive liposomal 
delivery at some doses but only if the blood was not significantly heated.  
2.3.3. Transport in Interstitial Space 
Following extravasation, drugs move in the interstitial space to reach tumour cells. The main 
pathways for drug movements are also attributed to convection and diffusion, which are highly 
dependent on interstitial fluid pressure and interstitial fluid velocity within tumour. Drug 
convection in interstitium is determined by hydraulic conductivity and pressure gradient, and 
diffusion depends on the concentration gradient and diffusion coefficient. Diffusion within a 
tissue is slower than diffusion through a medium filled with interstitial fluid, due to the presence 
of cells [46]. The composition of the extracellular space also affects the diffusivity of compounds 
through tissue, especially for macromolecules which are mostly influenced by the presence of 
proteins in interstitial fluid. The fact that diffusivity also depends on the architecture of tissue [46] 
means that the diffusion coefficient for the same drug can be different in tumour and normal 
tissue.  
In the work of Netti [91], the tumour was modelled as a poroelastic material. The aim was to 
determine the mechanisms regulating interstitial fluid pressure and develop methods to overcome 
the interstitial fluid pressure barrier in drug delivery. Experimental and numerical results 
demonstrated that higher uptake of macromolecular would result from periodic modulation of 
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blood pressure rather than acute or chronic increase of intravascular pressure. Hence pressure 
elevation caused by drug administration would have a limited effect on drug delivery.  
Goh [51] develop a 2-D simulation platform to investigate the spatial and temporal variation of 
doxorubicin concentration in hepatoma. The model geometry was reconstructed from patient-
specific CT images, including the necrotic core, viable tumour and its surrounding normal tissue. 
Increase in vascular pressure caused by intravenous bolus injection was considered, and the 
predicated results showed that interstitial fluid pressure stabilized fairly quickly. The results also 
indicated that diffusion was the dominant transport mechanism. It was concluded that 
doxorubicin transport to solid tumour was strongly dependent on the vascular exchange area, 
doxorubicin cellular metabolism and DNA binding kinetics.   
The effect of transient interstitial fluid flow on drug delivery in brain tumour was addressed by 
Teo [79]. After surgical removal of the necrotic core, polymer wafers that contained bis-
chloroethylnitrosourea (BCNU) were implanted in the cavity. The mathematical platform 
established by Goh [51] was applied to simulate the intra-tumoural release of BCNU and its 
penetration through resection cavity to the tumour. The interstitial fluid flow was found to reach 
equilibrium in less than 3 hours, and surgery could only enhance drug delivery temporally.  
Owing to the presence of a variety of proteins and nucleic acids in the interstitial space, 
extensive binding may take place. Experimental studies have shown that binding can delay drug 
transport [92-94]. In an experiment on thyroid cancer cells, 5-fluorouracil, cisplatin and inulin 
were found to be evenly distributed in cell spheroids within 15 minutes [17, 93, 94], while 
doxorubicin, methotrexate and paclitaxel, which bind to macromolecules, remained in the 
periphery of spheroids [95-97]. Since a tumour is always surrounded by normal tissues and 
interstitial fluid velocity is higher at the periphery of tumour than in the centre, drug exchange 
can also take place between tumour and normal tissues.  
Based on a computational reaction-diffusion model, Tzafriri [80] examined drug release from 
intra-tumourally injected microspheres and drug transport in an idealized tumour model 
accounting for binding in tumour interstitial fluid. Their simulation results suggested that 
extracellular drug concentration was spatially heterogeneous in the initial period following drug 
administration. It was concluded that increasing the duration of drug release might prolong the 
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exposure duration of anticancer drug but lower the plateau drug concentration. This implied that 
intratumoural drug release could be optimized to improve treatment efficacy. 
Baxter and Jain [88] developed a general theoretical framework to examine the effect of binding 
on concentration profiles of macromolecules. A high binding affinity was predicted to be most 
efficacious except for certain conditions of necrotic cores and low vascular permeability. 
Doxorubicin was also found to bind extensively with proteins, mainly albumin, in both plasma 
and interstitial fluid [55]. Due to the lack of in vivo experimental data, Eikenberry [90] assumed 
that doxorubicin binding and unbinding in both plasma and interstitial fluid shared the same rates, 
which were obtained based on experimental data [86]. Coupled with other drug transport 
processes including transvascular and interstitial movement, drug binding was investigated in a 
tumour core model. Their simulation results showed that most of the doxorubicin in extracellular 
space existed in bound form.  
2.3.4. Transport to Lymphatic System 
The lack of a functional lymphatic system has been observed in solid tumours [49, 50]. The 
limited existence of the lymphatic system can significantly reduce the clearance of large 
molecular weight drugs and hence increase their retention in interstitial fluid. These are typically 
liposome, nanoparticles and macromolecular drugs. On the other hand, without effective 
drainage of interstitial fluid from the extracellular space, interstitial fluid pressure will increase, 
which will in turn affect the drug exchange between blood and interstitial space.  
Based on  previous work on interstitial fluid pressure and drug convection, Baxter and Jain [50] 
used a similar model to examine the effect of lymphatics on interstitial fluid pressure distribution 
and concentration distribution of macromolecules (e.g. antibody). Their results suggested that 
substances could be rapidly removed by lymphatics, if present in tumour, which would result in 
much lower concentration levels.  
2.3.5. Transport through Cell Membrane 
After migrating in the interstitial space, drug can pass through cell membrane to enter tumour 
cells. The main mechanisms for molecular transit across membranes are passive diffusion, 
diffusion through channels, facilitated and active transport which involves the participation of 
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transmembrane proteins that bind a specific solute [46]. Drug transport through cell membrane is 
a dynamics process, with influx and efflux occurring simultaneously [46, 90]. Dordal [98] 
monitored cellular uptake of fluorescence-labelled doxorubicin in human lymphoma cells by a 
flow cytometry assay with a rapid-injection system. The experimental data was then analysed by 
a pharmacokinetic model to find the relation between drug concentration and cellular uptake.  
Tumour cells can become resistant to anticancer drugs. One of the complex resistance 
mechanisms is related to a 1.7×10
5 
Da membrane protein named P-glycoprotein (P-gp). Being 
insensitive to a wide variety of chemicals, P-gp is capable of actively transporting certain types 
of anticancer drugs, including doxorubicin and vincristine. Luu [99] developed a mathematical 
model to capture the efflux of doxorubicin resulting from drug mediated P-gp induction, and 
they concluded that their mathematical model could be utilized to optimize dosing strategies in 
order to minimize P-gp induction and thereby improving treatment efficacy. 
El-Kareh and Secomb [55] included the dynamic process of cellular uptake and efflux in a 
symmetric tumour model to investigate the influence of administration modes. Friedmen [100] 
adopted a simplified model to fit cellular uptake rate data that showed saturation in both intra- 
and extra-cellular concentrations. Kerr’s [101] experiments provided the experimental support to 
this mathematical model. Cell uptake and efflux were analysed by human non-small cell lung 
tumour cells in monolayer culture, and the relation between intracellular drug concentration and 
cytotoxicity was obtained. A similar model was improved by Eikenberry [90] and then adopted 
by Liu [102] to investigate the eﬀects of ATP-binding cassette transporter-based acquired drug 
resistance mechanisms at the cellular and tissue scale.   
2.3.6. Cell Killing 
After phagocytosis by tumour cells, drugs may destroy the genes that cause cells to divide or 
interrupt the chemical process involved in cell division, and thereby killing cells. The rate of cell 
killing has been found to be strongly dependent on extracellular and intracellular drug 
concentrations, and several models have been proposed to describe this relationship. 
The cytotoxicity of drug was firstly assumed to be a function of area under the extracellular 
concentration-time curve (AUCe) [103]. Ozawa [104] derived a cell kill kinetics equation for cell 
cycle phase-non-specific agents, and tested the equation by fitting to experimental results based 
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on Chinese hamster V79 cells. It was concluded that the cell killing action of cell cycle phase-
non-specific drugs could be described by a pharmacodynamics model with the concentration-
time product. Eichholtz-Wirth [105] treated Chinese hamster cells and Hela cells with 
doxorubicin, and found the surviving cell fraction was proportional to the product of 
extracellular drug concentration and exposure time. The experimental data also showed a non-
linear relation between extra- and intra-cellular concentrations. 
Although there is evidence that drug can kill cells without entering them, cell death is believed to 
be mainly dependent on intracellular concentration [1, 106]. Alternative models including 
intracellular drug concentration and cellular pharmacodynamics have been proposed. A cellular 
pharmacodynamics model for cisplatin was proposed by El-Kareh and Secomb [107] to relate 
cell killing to the peak value of intracellular concentration over the entire treatment period. The 
kinetics equations were modified for doxorubicin to reflect survival cell fraction [55, 90]. 
However, this model is incapable to tracking the dynamic variation of tumour cell density.  
Given that chemotherapy is a dynamic process including cell proliferation, physical degradation 
and cell killing caused by drugs, a dynamic model was suggested to evaluate the temporal 
variation of cytotoxic effect of anticancer drugs [102]. Lankelma [108] proposed a 
pharmacodynamics model for doxorubicin, where cell killing was described as a function of 
intracellular concentration history. Drug accumulation history in cells was calculated using 
cellular drug transport parameters derived from doxorubicin uptake and efflux measurements on 
MCF-7 cells attached to culture dishes. Eliaz [109] developed a model taking into account the 
cell proliferation rate, the cell killing rate, the average intracellular concentration and a lag time 
for cell killing. The model was applied to free doxorubicin and doxorubicin encapsulated in 
liposome targeted to melanoma cells in culture. 
2.4. Summary 
A detailed review of tumour characteristics, drug delivery methods and transport processes 
indicates that all these three aspects depend on and interact with each other during anti-tumour 
treatment. Although previous studies summarized in this chapter have addressed the complex 
interplays among these factors to a certain extent, a systematic study that accounts for all these 
physical and biological aspects is lacking. This is what the current project aims to achieve, and 
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the integrated mathematical model developed in this project will serve as a platform to compare 
and optimise different strategies in chemotherapy. 
 
  
 
 
 
 
 
 
 
 
 
3.  Mathematical Models and Numerical 
Procedures 
 
In this chapter, a detailed description of mathematical models and their 
implementations are given. The mathematical equations are described first; these 
include equations governing the interstitial fluid flow in tumour and normal tissues, 
mass transport and cellular uptake of anticancer agents, and heat transfer in response 
to the application of HIFU for activation of drug release from thermo-sensitive 
liposomes. Model parameters as well as relevant physical and transport properties are 
then discussed. Finally, numerical methods to implement the mathematical models 
are presented. 
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3.1. Mathematical Models 
Drug properties are the key factors in anticancer treatments. In addition, drug transport also 
depends on the interstitial fluid flow in tumour and its holding tissue, and the properties of 
tumour cells have impacts on the cell killing as well. To include these relationships, the current 
modelling platform consist of descriptions of interstitial fluid flow, transport for none-
encapsulated and thermo-sensitive liposome-mediated drugs, pharmacodynamics of tumour cells 
and bioheat transfer model introduced by high intensity focus ultrasound heating for thermo-
sensitive liposome-mediated drugs only. Given the mentioned fact that the large size difference 
exist between a tumour and its vasculature, a commonly adopted approach for study on drug 
transport is treating the vasculature as a source term in the governing equations, without 
considering its morphological features. The main assumptions are as follows: (1) the interstitial 
fluid is incompressible, Newtonian fluid with homogeneous properties in tumour and 
surrounding normal tissue, respectively; (2) all tumour cells are stationary, identical and alive 
initially; (3) the simulation duration is significantly shorter than the timescale for tumour growth, 
and thereby the physiological parameters and geometry are independent of time.  
The mathematical models consist of the mass and momentum conservation equations for 
interstitial fluid flow, mass transfer equations for the free and bound drug, transport equations for 
liposome encapsulated drug, as well as equations describing the intracellular drug concentration 
and pharmacodynamics. First, the interstitial fluid flow equations are solved to provide the basic 
biomechanical environment for drug transport. This is followed by solution of the mass transfer 
equations for drug transport, which is described schematically in Figure 3-1 (a) and (b) for direct 
infusion, and thermo-sensitive liposome-mediated delivery of doxorubicin, respectively. Briefly, 
the tumour region consists of three compartments: blood, extracellular space and tumour cells. 
Within each compartment, letters F, B and L represent free, bound and liposome encapsulated 
doxorubicin, respectively. 
The dynamics process in drug delivery includes association/disassociation with protein at the rate 
kas and kds respectively, drug exchange between blood and extracellular space, and influx/efflux 
of drugs from extracellular space to tumour cells. The rate of cell killing is governed by a 
pharmacodynamics model based on the predicted intracellular concentration of anticancer drugs. 
In the case of thermo-sensitive liposome-mediated drug delivery, an additional equation 
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describing the transport of liposomes is needed. The detailed descriptions of each section of 
mathematical models are listed below.   
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Figure 3-1. Drug transport with (a) continuous infusion of drug in its free form, and (b) thermo-sensitive liposome-
mediated drug delivery 
3.1.1. Interstitial Fluid Flow 
The mass conservation equation for interstitial fluid is given by 
   
lyv FF  v                                                             (3-1) 
where v is the velocity of the interstitial fluid, Fv and Fly are the source and sink terms, 
accounting for the gain of interstitial fluid from blood vessels, and fluid absorption rate by the 
lymphatics, respectively. Fv and Fly can be determined by Starling’s law 
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  ivTivvv pp
V
S
KF                                                      (3-2) 
where Kv is the hydraulic conductivity of the microvascular wall, S/V is the surface area of blood 
vessels per unit volume of tumour tissue, pv and pi are the vascular and interstitial fluid pressures, 
respectively, σT represents the average osmotic reflection coefficient for plasma protein, πv is the 
osmotic pressure of the plasma, and πi is that of interstitial fluid.  
The lymphatic drainage, Fly, is related to the pressure difference between the interstitial fluid and 
lymphatics.  
 lyi
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lyly pp
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KF                                                         (3-3) 
where Kly is the hydraulic conductivity of the lymphatic wall, Sly/V is the surface area of 
lymphatic vessels per unit volume of tumour tissue, and ply is the intra-lymphatic pressure.  
The tumour and its surrounding tissues are treated as porous media, which can be justified as the 
inter-capillary distance (33-98 µm [21, 110]) is typically 2-3 orders of magnitude smaller than 
the length scale for drug transport. The corresponding momentum equation is given by 
 
  Fτvv
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where the stress tensor τ is expressed as 
Ivvvτ )(
3
2
])([   T                                                (3-5) 
where ρ and μ is the density and dynamic viscosity of interstitial fluid, respectively. I is the unit 
tensor. The last term in equation (3-4), F, represents the Darcian resistance to fluid flow through 
porous media and is given by 
vvCvF 
2
1
W                                                        (3-6) 
and W is a diagonal matrix with all diagonal elements calculated as 
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1 W                                                                 (3-7) 
where C is the prescribed matrix of the inertial loss term, and κ is the permeability of the 
interstitial space. Since the interstitial fluid velocity is very slow (|v|<<1) [49], the inertial loss 
term can be neglected when compared to the Darcian resistance. In addition, the interstitial fluid 
is treated as incompressible with a constant viscosity. Hence, equation (3-6) can be reduced to 
vF W                                                                (3-8) 
3.1.2. Drug Transport  
Drug transport is governed by the convection-diffusion equations for the free and bound drug in 
the interstitial fluid. Free doxorubicin concentration in the interstitial fluid (Cfe) is described by  
 
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2                                             (3-9) 
where Dfe is the diffusion coefficient of free doxorubicin. The source term, Si, is the net rate of 
doxorubicin gained from the surrounding environment, which is given by 
ubvi SSSS                                                         (3-10) 
here Sv, Sb and Su represent the net rate of doxorubicin gained from the blood/lymphatic vessels, 
association/dissociation with bound doxorubicin-protein and influx/efflux from tumour cells, 
respectively.   
flfpv FFS                                                           (3-11) 
where Ffp is the doxorubicin gained from the blood capillaries in tumour and normal tissues, and 
Ffl is the loss of doxorubicin to the lymphatic vessels per unit volume of tissue. Using the pore 
model [49, 50, 87, 89] for trans-capillary exchange, Ffp and Ffl can be expressed as 
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felyfl CFF                                                            (3-13) 
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where Cfp is the concentration of doxorubicin in blood plasma, σd is the osmotic reflection 
coefficient for the drug molecules, and Pfe is the permeability of vasculature wall to free 
doxorubicin. Pef is the trans-capillary Peclet number defined as 
 
V
S
P
F
fe
dv 
1
Pef                                                        (3-14) 
The net doxorubicin gained due to protein binding and cellular uptake is governed by  
feabedb CkCkS                                                      (3-15) 
ζDDS ccu                                                          (3-16) 
where Dc is the tumour cell density, ka and kd are the doxorubicin-protein binding and 
dissociation rates, respectively. 
The convection-diffusion equation for bound doxorubicin (Cbe) is similar to equation (3-9) 
except for the source terms.  
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where Dbe is the diffusion coefficient of the bound doxorubicin-protein, and Fbe accounts for the 
gain of bound doxorubicin from blood vessels, which is given by 
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where Pbe is the permeability of the vessel wall to bound doxorubicin, and Cbp is the bound 
doxorubicin concentration in the plasma. The trans-capillary Peclet number is  
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Since only unbound doxorubicin can pass through the cell membrane [55, 90], the rate of cellular 
uptake is a function of free doxorubicin concentration in the interstitial fluid.  
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where Ci is the intracellular doxorubicin concentration, and Vmax is the rate of trans-membrane 
transport, ζ and ɛ are cellular uptake and efflux functions, ke and ki are constants obtained from 
experimental data, and φ is the volume fraction of extracellular space. 
3.1.3. Thermo-Sensitive Liposome-Mediated Drug Transport 
Additional equations are required to describe the transport of liposome encapsulated doxorubicin, 
in order to solve separately the encapsulated drug concentration and released drug concentration. 
Equations for the transport of released drug, including those for free drug concentration in 
plasma and interstitial fluid, bound drug concentration in plasma and interstitial fluid as well as 
intracellular concentration, are described using the same equations given in the preceding section. 
Similar to equation (3-9), the liposome encapsulated drug concentration in the interstitial fluid 
(Cle) is governed by 
  llelle
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where Dl is the diffusion coefficient of liposomes. The source term, Sl is the net rate of liposomes 
gained from the surrounding environment, which is given by 
rlpl SSS                                                            (3-24) 
Here, Slp represents the liposomes gained from plasma, and Sr represents released drug in the 
interstitial fluid. Slp can be calculated by 
lllplp FFS                                                          (3-25) 
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where Flp is the liposomes gained from the capillaries in tumour and normal tissues, and Fll is the 
loss of liposomes through the lymphatic vessels per unit volume of tissue. Values for Flp and Fll 
can be obtained using the pore model described by Equations (3-12) to (3-14) but with transport 
properties corresponding to the thermo-sensitive liposome. 
The amount of released doxorubicin in the interstitial fluid, Sr, is given by 
lerelr CkS                                                             (3-26) 
where krel is the release rate of doxorubicin from liposome. 
The free doxorubicin concentration in blood plasma (Cfp) is governed by 
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where Ffp represents the free doxorubicin crossing the capillary wall into the interstitial fluid. VT 
and VB are tumour volume and blood plasma volume, respectively. CLfp is the plasma clearance 
of drug. ka and kd are the association and disassociation rates with proteins.   
The bound doxorubicin concentration in blood plasma (Cbp) is given by 
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where CLbp is the plasma clearance of bound doxorubicin.  
The free doxorubicin concentration in interstitial fluid (Cfe) is described by Equation (3-9), 
except that the source term contains an additional contribution from Sr, as described below. 
rubvi SSSSS                                                     (3-29) 
Expressions for the terms on the right hand side have been given previously (see equations (3-11) 
to (3-16) and (3-26)). 
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3.1.4. Pharmacodynamics Model 
The change of tumour cell density with time is described by a pharmacodynamics model as 
given below [109].  
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The first term on the right hand side represents the anticancer effect, where fmax is the cell-kill 
rate constant and EC50 is the drug concentration producing 50% of fmax. kp and kg are cell 
proliferation rate constant and physiological degradation rate, respectively. In this study, cell 
proliferation and physiologic degradation are assumed to have reached equilibrium at the start of 
each treatment.  
3.1.5. Heat Transfer under High Intensity Focused Ultrasound (HIFU)  Heating 
In localized heating in anti-tumour therapy, both blood and tissue including the tumour and its 
holding tissue are heated. Energy balances for tissue and blood are illustrated in Figure 3-2 (a) 
and (b), respectively. 
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Figure 3-2. Schematic representation of heat transfer under HIFU heating in (a) tumour and (b) blood 
The temperature (T) of tissue and blood can be calculated by solving the following energy 
balance equations [74, 111]: 
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where ρ is the density, c is the specific heat, k is the thermal conductivity, and w is the perfusion 
rate of blood flow. q represents the ultrasound power deposition, and subscripts b and t represent 
blood and tissue, respectively. Tn is the normal body temperature, which is assumed to be 37 ˚C.  
In reality, heating of biological tissue by HIFU also contains the effect of acoustic non-linearity 
[112, 113]. However, studies show that the non-linear wave propagation can be ignored if a focal 
intensity is within the range of 100~1000 W/cm
2
 and the peak negative pressure in the range of 
1~4 MPa [74, 114]. The ultrasound power deposition per unit volume is assumed to be 
proportional to the local acoustic intensity Ia as follows  
aIq 2                                                              (3-33) 
where α is the absorption coefficient, and the intensity Ia is defined as: 
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va is the speed of ultrasound, and pa is the acoustic pressure which is represented by the real parts 
of the following equation 
 aaca vikp                                                           (3-35) 
here kac represents the acoustic velocity potential, and is given by 
 
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a
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k                                                        (3-36) 
ω is the angular frequency, and λ is the wave length of ultrasound.  
For a spherical concave radiator S (Figure 3-3) with a uniform normal velocity, if the diameter or 
width of a slightly curved radiator is large compared to the wave-length, the resulting acoustic 
velocity potential, Ψ, in a restricted region can be written as [115] 
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where u is the normal velocity of a slightly curved radiating surface, which is represented by 
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tieu 0u                                                                 (3-38) 
here u0 is a constant and t is time. In Equation (3-37), d is the distance from a point on the 
radiator to a field point, which is given by  
2
11
2 cossin2 zRRrRd                                              (3-39) 
2cos21 bhRz                                                          (3-40) 
 22111 41 ARRr                                                     (3-41) 
Referring to Figure 3-3, the ultrasound radiator is represented by the thick lines and the heated 
point is Q. A and a are the radius of curvature and radius of the circular boundary, respectively, h 
is the depth of the concave surface and b is the chord from the transducer centre O to the radiator 
boundary. 
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Figure 3-3. Dimensions and coordinates of a spherical radiator [115]. 
3.2. Model Parameters 
Since the growth of tumour and normal tissues is ignored, all the geometric and transport 
parameters used in this study are assumed to be independent of time. Values adopted for these 
are summarized in Tables 3-1, 3-2 and 3-3 at the end of this Chapter for parameters related to the 
tissue, liposome and doxorubicin, respectively. Justifications for the choices of some of the 
parameters are given below. 
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3.2.1. Tissue Related Transport Parameters 
Blood vessel surface area to tissue volume ratio (S/V) 
The ratio of surface area of blood vessel to tissue volume has a direct influence on the amount of 
anticancer drug in the interstitial fluid. Its value depends strongly on the type of tissue and stage 
of tumour growth [116]. Pappenheimer et al. measured this in normal tissues [117], while Baxter 
and Jain [49] recommended using 70 cm
-1
 and 200 cm
-1
 for normal and tumour tissues, 
respectively. The effect of this parameter on anticancer efficacy and its derivation from in vivo 
MR images will be discussed in Chapter 5.  
Tumour cell density (Dc) 
The volume fraction of extracellular space in a tumour tissue ranges from 0.2 to 0.6 [118]. 
Assuming an average tumour cell diameter, Eikenberry [90] estimated that tumour cell density 
ranged from 9.55×10
15
 to 1.53 ×10
16
 cells/m
3
. During chemotherapy treatment, tumour cell 
density may change as a result of drug uptake, cell proliferation and physiological degradation. 
3.2.2. Drug Related Transport Parameters 
Vascular Permeability (P) 
Vascular permeability coefficient measures the capacity of a blood vessel (often capillary in 
tumour) wall to allow for the flow of substances in and out of the vasculature. The structure of 
vessel wall and the molecular size of the transported substance are key determinants of 
permeability [110]. 
(1) Free & bound doxorubicin 
Estimates of this parameter reported in the literature usually correspond to ‘effective 
permeability’, which is on the order of 10-7 m/s for albumin in both tumour and normal tissues. 
For Sulforhodamine B (MW=559 Da), its permeability in normal tissue is 3.4×10
-7
 m/s [119]. 
Patent is another agent with a similar molecular weight (566 Da) to that of doxorubicin, and its 
permeability is 3.95×10
-7
 m/s in normal tissue of male frog [120]. Eikenberry [90] assumed the 
effective permeability of free doxorubicin in tumour to be in the range of 8.1×10
-7
 and 3.7×10
-6
 
m/s, whereas Ribba et al. [121] used 3.0×10
-6
 m/s in their simulation work. Compared with 
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normal tissues, Gerlowski and Jain [122] found the vessel wall permeability to be 8 times higher 
in tumour tissues. Using MW for interpolation, Goh [51] assumed the permeability of 
doxorubicin in tumour tissue to be nearly 8 times higher than in normal tissue. In the present 
study, values of permeability in tumour and normal tissues are assumed to be 3.0×10
-6
 m/s and 
3.75×10
-7
 m/s, respectively. Wu et al. [119] measured the permeability of albumin 
(corresponding to albumin-bound doxorubicin) in both tumour and granulating tissues, and found 
the corresponding vasculature permeability to be 7.8±1.2×10
-9
 m/s and 2.5±0.8×10
-9
 m/s, 
respectively. In this thesis, their average value is adopted as the permeability of albumin-bound 
doxorubicin.  
(2) Liposome encapsulated doxorubicin 
The permeability of polyethylene glycol coated liposomes of 100 nm through tumour capillaries 
was measured at 37
 o
C by Yuan et al. [26] and Wu et al. [25] as 2.0×10
-10
 and 3.42±0.78×10
-9
 
m/s, respectively. In normal granulation tissues permeability of the same liposomes was 
8.0~9.0×10
-10
 m/s at the same temperature [25, 26]. 
Diffusion Coefficient (D) 
Diffusion coefficient is the constant of proportionality between the molar flux owing to 
molecular diffusion and the gradient in the concentration of the species, which is also known as 
the driving force for diffusion. 
(1) Free and bound doxorubicin 
Diffusion coefficient is related to the molecular weight (MW) of the substance [15]. The 
relationship between diffusion coefficient in water and molecular weight can be represented by 
[15, 123] 
  d2ad1w MWaD

                                                      (3-45)
 
This equation is used to fit the diffusion coefficients of common anticancer agents in water [124] 
(Figure 3-4). Since doxorubicin has a MW of 544 Da, its diffusion coefficient in water at 37 
o
C 
could be estimated as 3.83×10
-10
 m
2
/s. It has also been found that diffusion coefficient in 
neoplastic tissue deviates from free diffusion in water [118]. For MWs in the range of 376 Da and 
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66,900 Da, the ratio of diffusion coefficient in tumour (D) to that in water (DW) was found to be 
linearly related to MW  
d4d3
w
aMWa
D
D                                                    (3-46)
 
Using equation (3-46), the ratio for doxorubicin is 0.8885 and the diffusion coefficient of 
doxorubicin in tumour is 3.40×10
-10
 m
2
/s (Figure 3-4 (b)). 
At 37 
o
C, the relationship between diffusion coefficient (D) and MW in normal tissues may be 
obtained from in vitro experimental data [125]. 
   690003210778.1 75.08   MWMWD                              (3-47) 
Based on equation (3-47), the diffusion coefficient of doxorubicin in normal tissues is calculated 
as 1.58×10
-10
 m
2
/s.   
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Figure 3-4. Estimation of doxorubicin diffusion coefficient in tumour tissue. (a) The diffusion coefficient of 
anticancer drugs in water as a function of molecular weight, using equation (3-45) [15, 123]. For the best fitted 
curve for experimental data in reference [124], ad1 = 380.44, ad2 = 0.73. (b) The relation between diffusion 
coefficient ratio (tumour to water) and molecular weight. For the best fitted line using equation (3-46) to fit 
experimental data from reference [118], ad3 = -8.55948 10
-6
, ad4 = 0.89317. 
Doxorubicin can bind with high molecular weight proteins (e.g. albumin [90]) in the interstitial 
fluid. In such a case, the diffusion coefficient of the bound component depends mainly on the 
protein (e.g. albumin). The effective diffusion coefficient for albumin in VX2 carcinoma was 
measured as 8.89×10
-12
 m
2
/s [90]. Since the bound component has a MW of approximately 69 
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kDa [51], its diffusion coefficient in normal tissue estimated by Equation (3-47) is 4.17×10
-12
 
m
2
/s. 
(2) Liposome encapsulated doxorubicin 
For diffusion of spherical particles through liquid at low Reynolds number, the diffusion 
coefficient in water can be calculated by solving the Einstein-Stokes equation [15].  
r
Tk
D Bw 6
*

                                                        
(3-48) 
where kB is Boltzmann's constant, T* is the absolute temperature, μ is viscosity and r is the radius 
of spherical particle. Assuming the liposomes are spherical with a uniform diameter of 100 nm, 
their diffusion coefficient at 37
o
C is 5.82×10
-12 
m
2
/s. 
Yuan found that for liposome particles of 90 nm in diameter, the ratio of permeability in tumour 
and diffusion coefficient in water was around 20 m
-1
 [110], and the permeability was 
2.0±1.6×10
-10 
m/s [26]. Based on these results, the diffusion coefficient is 1.0±0.8×10
-11 
m
2
/s. 
Based on the Einstein-Stokes equation, the diffusion coefficient is inversely related to the 
particle radius. Hence, the diffusion coefficient of liposomes with 100 nm diameter is estimated 
to be 9.0±7.2×10
-12
 m
2
/s. The diffusion coefficients in tumour and normal tissues adopted in this 
thesis are 9.0×10
-12 
m
2
/s and 5.8×10
-12 
m
2
/s, respectively.  
Reflection Coefficient (σ) 
The reflection coefficient determines the efficiency of the oncotic pressure gradient in driving 
transport across the vascular wall. It is related to the sizes of drug and pores on the vasculature 
wall [126]. For the same drug, this parameter may vary in different types of tissues [127].  Wolf 
et al. [128] measured the reflection coefficient for albumin and found this to be 0.82±0.08. The 
sizes of albumin and liposome are 3.5 nm and 100 nm, respectively. The reflection coefficient 
for liposome is estimated to be greater than 0.90, hence it is assumed to be 0.95 in this study. 
Drug Dose (Dd) 
As a common anticancer drug, doxorubicin is widely used in chemotherapy to treat various types 
of cancer, such as lymphoma, genitourinary, thyroid, and stomach cancer [3]. By interacting with 
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DNA in cells, doxorubicin can inhibit the process of DNA replication. Because of this 
mechanism of action, high concentration of doxorubicin in normal tissues can cause serious 
damage to healthy cells, known as side effects. In clinical therapy, the most serious toxicity is 
life-threatening cardiomyopathy [129, 130], leading to heart failure. Side effects set a limit to the 
lifetime dose a patient can receive, which is approximately 550 mg per unit body surface area [3]. 
The dose of doxorubicin in clinical use is related to the patient’s body surface area. In each 
treatment cycle, the dose is between 50 to 75 mg/m
2
 [3].   
Plasma Pharmacokinetics (Cv) 
Doxorubicin concentration in blood plasma is modelled as an exponential decaying function of 
time. The form of equations depends on the infusion mode. 
For continuous infusion, a tri-exponential decay is assumed based on the plasma 
pharmacokinetics of doxorubicin [55, 90]. 
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where t refers to time, Dd is the dose of doxorubicin and Td is the infusion duration. A1, A2 and A3 
are compartment parameters and α1, α2, α3 are compartment clearance rate. 
For bolus injection, the terms involving α2, α3, A2 and A3 represent the compartments with much 
slower elimination. The drug concentration is assumed to follow an exponential decay based on 
the plasma pharmacokinetics of doxorubicin [55, 90]. 
tα
dv eADC
1
1
                                                         (3-50) 
Free doxorubicin in plasma can easily bind with proteins, such as albumin. Greene et al. [86] 
found that approximately 75±2.7 % doxorubicin is present in the bound form, and the percentage 
binding is independent of doxorubicin and albumin concentrations. Hence for direct infusion, the 
free (Cfp) and bound (Cbp) doxorubicin concentrations in plasma are given by: 
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                                                        (3-51) 
where s is the percentage of bound doxorubicin, which is 25% in this study.  
3.3. Implementations of Mathematical Models 
Usually the location where anticancer agents are administrated into a patient’s body is remote 
from the tumour, hence the influence of drug infusion on blood pressure in the tumour is ignored. 
In addition, drug transport processes are assumed to have no influence on the interstitial fluid 
pressure because of the small size of anticancer agents. In order to generate initial conditions for 
the time-dependent numerical simulation, the interstitial fluid flow equations are firstly solved to 
obtain a steady-state solution in the entire computational domain. Following this, the obtained 
pressure and velocity values are applied at time zero for the simulation of drug transport and 
cellular uptake in order to predict the treatment efficacy. The mathematical equations described 
above are implemented into ANSYS Fluent, which is described in the following section. 
3.3.1. ANSYS Fluent 
ANSYS FLUENT is a widely used CFD code based on the finite volume method (FVM). The 
physical domain is firstly divided into a large number of computational cells forming a 
computational grid on which control volumes are defined where the variable of interest is located 
in the centroid. Governing equations in the differential forms are then integrated over each of the 
control volumes until the residual between two adjunct iterations is less than a given tolerance. 
The conservation principle for the variables in each control volume is expressed by the resulting 
discretised equation.     
The employed solution algorithm is the SIMPLEC which uses a relationship between velocity 
and pressure corrections to enforce mass conservation and to obtain the pressure field. The 
momentum, mass and heat transfer equations are discretised using the second order UPWIND 
scheme, in which quantities at cell faces are computed using a multi-dimensional linear 
reconstruction approach [131]. In this approach, higher-order accuracy is achieved at cell faces 
through a Taylor series expansion of the cell-centred solution about the cell centroid. For 
  vbp
vfp
CsC
sCC


1
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transient problems, a fully implicit second order backward Euler scheme is adopted, which is 
unconditionally stable with respect to time step size. The Gauss-Seidel method is adopted to 
update values at nodal points by using the previously computed results as soon as they become 
available. 
3.3.2. User Defined Routines for Drug Transport 
Mass transfer equations describing the transport of drugs are coded in C programming language 
by using the User Defined Scalar (known as UDS), which is a function for user defined 
programme be dynamically loaded with FLUENT. 
These equations are solved based on the interstitial fluid field resolved by solving the continuity 
and momentum equations. Drug transport equations are also discretised using the second order 
UPWIND scheme, and the tolerance controlling the convergence is set to be 1×10
-8
. 
3.3.3. User Defined Routines for Heat Transfer 
Heat transfer under HIFU heating in blood and tissue is also incorporated via UDS. These 
equations are solved with the drug transport equations when simulating thermo-sensitive 
liposome-mediated drug delivery. The second order UPWIND scheme is adopted for spatial 
discretisation and the convergence tolerance is set as 1×10
-10
. 
3.3.4. Boundary Conditions 
In order to solve the above equations numerically and to ensure physiological relevance of the 
solutions, each of the dependent variable equations requires meaningful values at the boundary 
of the computational domain. These values are known as boundary conditions. Typical 
boundaries involved in the problems dealt with in this thesis include: interface between tumour 
regions, tumour-normal tissue interface and external surface of normal tissue. The specification 
of boundary conditions is problem-dependent, hence details will be given for each problem 
described in individual chapters. 
3.4. Summary 
The numerical methods and tools described above were applied to a realistic prostate tumour 
with a focus on understanding the transport steps of non-encapsulated drugs (Chapter 4), a liver 
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tumour with a focus on elucidating the effect of heterogeneous distribution of blood vessels and 
3 prostate tumours with a focus on examining the effect of tumour size and microvascular 
density (Chapter 5), and a realistic prostate tumour with a focus on investigating the thermo-
sensitive liposome-mediated drug delivery with hyperthermia induced by high intensity focused 
ultrasound (Chapter 6). All computations were carried out on an HP Compaq 8100 Elite CMT 
PC. 
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Table 3-1. Parameters for tumour and normal tissues. 
Parameter  Definition Unit Tumour Tissue Normal Tissue Reference 
S/V Surface area of blood vessels per unit tissue volume m
-1 
20000 7000 [49-51, 88] 
Kv Hydraulic conductivity of the micro-vascular wall m/Pa·s 2.10×10
-11
 2.70×10
-12
 [49-51, 88] 
ρ Density of interstitial fluid kg/m3 1000 1000 [51] 
µ Dynamic viscosity of interstitial fluid kg/m·s 0.00078 0.00078 [51] 
1/κ Permeability of the interstitial space m-2 4.56×1016 2.21×1017 [49-51, 88] 
pv Vascular fluid pressure Pa 2080 2080 [49-51, 88] 
πv Osmotic pressure of the plasma Pa 2666 2666 [49-51, 88] 
πi Osmotic pressure of interstitial fluid Pa 2000 1333 [49-51, 88] 
σT Average osmotic reflection coefficient for plasma proteins  0.82 0.91 [49-51, 88] 
KlySly/V Hydraulic conductivity of the lymphatic wall times surface 
area of lymphatic vessels per unit volume of tumour tissue 
(Pa·s)
-1 
0 4.17×10
-7
 [51] 
ply Intra-lymphatic pressure Pa 0 0 [51] 
Dc Cell density 10
5
cell/m
3 
1×10
10 
- [90] 
VT Total tumour volume m
3 
5×10
-5
 3×10
-4
 [55] 
VB Total blood volume in body m
3
 5×10
-2
 5×10
-2
 [55] 
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Table 3-2. Parameters for liposome 
Parameter Definition Unit in Tumour in Normal Tissue Reference 
Pl Liposome permeability of vasculature wall m/s 3.42×10
-9
 8.50×10
-10
 [25, 26] 
D Liposome diffusion coefficient m
2
/s 9.0×10
-12
 5.8×10
-12 
[25, 110] 
σl Reflection coefficient for liposome  0.95 1.0 - 
CLlp Plasma clearance in tumour
 
s
-1 
2.228×10
-4
 2.228×10
-4
 [62] 
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Table 3-3. Parameters for doxorubicin. 
Parameter Definition Unit Free Doxorubicin Bound Doxorubicin Reference 
Ptumour Permeability of vasculature wall in tumour m/s 3.00×10
-6
 7.80×10
-9
 [51, 119] 
Pnormal Permeability of vasculature wall in normal tissue  m/s 3.75×10
-7
 2.50×10
-9
 [51, 119] 
Dtumour Diffusion coefficient in interstitial fluid of tumour m
2
/s 3.40×10
-10
 8.89×10
-12  
[15, 51, 118, 123-125] 
Dnormal Diffusion coefficient in interstitial fluid of normal tissue m
2
/s 1.58×10
-10
 4.17×10
-12
 [15, 51, 118, 123-125] 
σd Osmotic reflection coefficient   0.15 0.82 [51, 128] 
ka Doxorubicin-protein binding rate s
-1
 0.833 - [90] 
kd Doxorubicin-protein dissociation rate s
-1
 - 0.278 [90] 
φ Tumour fraction extracellular space  0.4  [90] 
Vmax Rate of trans-membrane transport kg/10
5
cells s 4.67×10
-15
 - [90, 101] 
ke Michaelis constant for transmembrane transport kg/m
3 
2.19×10
-4
 - [90, 101] 
ki Michaelis constant for transmembrane transport kg/10
5
cells 1.37×10
-12 
- [90, 101] 
fmax Cell-kill rate constant s
-1 
1.67×10
-5
 - [109] 
EC50 Drug concentration producing 50% of fmax kg/10
5
cells 5×10
-13
 - [109] 
A1 parameter for pharmacokinetic model m
-3 
74.6 74.6 [85, 90] 
A2 parameter for pharmacokinetic model m
-3
 2.49 2.49 [85, 90] 
A3 parameter for pharmacokinetic model m
-3
 0.552 0.552 [85, 90] 
α1 compartment clearance rate s
-1
 2.43×10
-3
 2.43×10
-3
 [85, 90] 
α2 compartment clearance rate s
-1
 2.83×10
-4
 2.83×10
-4
 [85, 90] 
α3 compartment clearance rate model s
-1
 1.18×10
-5
 1.18×10
-5
 [85, 90] 
kp Cell proliferation rate s
-1 
3.0×10
-6
 - [102] 
kg Cell physiologic degradation rate s
-1
 3.0×10
-16
 - [102] 
CLtumour Plasma clearance in tumour s
-1
 2.43×10
-3
 0 [85, 114, 132, 133] 
CLnormal Plasma clearance in normal tissue s
-1
 2.43×10
-3
 0 [85, 114, 132, 133] 
  
  
 
 
 
 
 
 
4.  Non-Encapsulated Drug Delivery to Solid 
Tumour 
 Intravenous administration of drugs in their free form is a traditional drug delivery 
method adopted in clinical treatments without specific targeting. Injected drugs 
undergo multiple transport processes in systemic blood stream, interstitial space and 
tumour cells. The role of drug transport in treatment efficacy is complicated because 
of nonlinear interactions between the drug and the microenvironment of tumour and 
surrounding normal tissues. An appropriate mathematical model is therefore needed 
to gain detailed understanding of the drug transport processes involved and how drug 
concentrations and its therapeutic effect may be influenced by infusion modes.  
In this chapter, a coupled pharmacokinetics and drug transport model is applied to a 
real tumour geometry reconstructed from magnetic resonance image (MRI) to 
examine the effects of various administration modes and clinic dose levels. This is 
followed by comparisons of drug concentrations and survival fraction of tumour cells 
between 2-D and 3-D geometry models. 
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4.1. Model Description 
The mathematic model described in Chapter 3 for free form drug administration is adopted, 
which incorporates the key physical and biochemical processes, including time-dependent 
plasma clearance, drug transport through the blood and lymphatic vessels, extracellular drug 
transport (convection and diffusion), drug binding with proteins, lymphatic drainage, interactions 
with the surrounding normal tissue and drug uptake by tumour cells. Anticancer efficacy is 
evaluated based on the percentage of survival tumour cells by directly solving the 
pharmacodynamics equation using the predicted intracellular drug concentration. 
4.1.1. Model Geometry 
The geometry of a prostate tumour is reconstructed from images acquired from a patient using a 
3.0-Tesla MR scanner (DISCOVERY MR750, GE, Schenectady, New York, USA). Multislice 
anatomical images of the prostate were acquired in three orthogonal planes with echo-planer (EP) 
sequence, with each image comprising 256 by 256 pixels. Other imaging parameters are given in 
Table 4-1.  
Table 4-1. MR imaging parameters 
Parameter 
(unit) 
Pixel Size 
(mm) 
Field of View 
(cm) 
Slice Thickness 
(mm) 
Repetition Time 
(ms) 
Echo Time 
(ms) 
 1.250 32.0 7.000 4000 84.4 
An example of the MR images is shown in Figure 4-1 (a) with the tumour region and its 
surrounding normal prostatic tissues. Transverse images are processed using image analysis 
software Mimics (Materialise HQ, Leuven, Belgium), and the tumour is segmented from its 
surrounding normal tissue based on signal intensity values. The resulting smoothed surfaces of 
the tumour and normal tissues are imported into ANSYS ICEM CFD to generate computational 
mesh for the entire volume.  
The tumour shown in Figure 4-1 (b) is located at the corner of normal tissue with a dimension of 
47 mm (maximum width) by 38 mm (maximum depth) in 2-D model.  The final mesh consists of 
64,966 triangular elements which have been tested to produce grid independent solutions.  
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Figure 4-1. Model geometry:  (a) MR image of the prostate tumour (in red) and its surrounding tissue (in pule blue); 
(b) the reconstructed 2-D geometry. 
4.1.2. Model Parameters 
The parameters describing general properties of doxorubicin, tumour and normal tissue have 
been given in Tables 3-1 and 3-3 in the preceding chapter. Infusion durations and doses 
simulated in this study are described below. 
(1) Infusion Duration 
Infusion duration is a key parameter in determining the pharmacokinetics of drug in blood. 
Previous experiments found that prolonged infusion, such as over 48 hours or 96 hours, did not 
contribution to better treatment efficacy [53, 54]. In a numerical study by [55], a 2-hour infusion 
was adopted without the consideration of cell proliferation and death as a dynamic process. 
Therefore, bolus injection and continuous infusion with infusion duration of 1-hour, 2-hour and 
3-hour respectively, are studied. 
(2) Infusion Dose 
Limited by the serious side effect caused by doxorubicin, the lifetime dose a patient can receive 
is approximately 550 mg per unit body surface area. For each treatment cycle, the dose is 
between 50 to 75 mg/m
2
 [3], depending on the body surface area of a patient.  
Body surface area (BSA) is determined from the following formula [51] 
                                           (4-1)  2
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For a 70 kg patient, dosage of doxorubicin is in the range of 86.5~129.75 mg. Three dose levels, 
50, 60 and 75 mg/m
2
 are examined in this study. 
(3) Pharmacokinetics 
Doxorubicin concentration in blood plasma is usually described by an exponential function over 
time. Better fit to the experimental data was found by using a 3-compartment model. 
For bolus injection and continuous infusion in a single administration, the plasma concentration 
of doxorubicin can be described by Equation (3-49) and (3-50), respectively. The plasma 
concentration in multiple administrations under bolus injection and continuous infusion are given 
below by Equation (4-2) and (4-3), respectively [134]. 
                                                     (4-2) 
 (4-3) 
where Dd is the dose of doxorubicin and Td is the infusion duration. A1, A2 and A3 are 
compartment parameters and α1, α2, α3 are compartment clearance rate. t
*
 is the time after n 
doses (i = 1,2,…,n) given at time tDi.  
To account for the high binding rate for doxorubicin with proteins, such as albumin in blood 
plasma, and for the fact that the percentage of bound doxorubicin is independent of plasma 
concentration of doxorubicin and albumin, the free (Cfp) and bound (Cbp) doxorubicin in blood 
are governed by Equation (3-51), where s is the percentage of bound doxorubicin, which is 0.25 
in this study [86]. 
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4.1.3. Numerical Methods 
The mathematical models described above are implemented in ANSYS-Fluent, which is a finite 
volume based computational fluid dynamics (CFD) code (ANSYS Inc., Canonsburg, USA). The 
momentum and drug transport equations are discretised using the second order UPWIND scheme, 
and the SIMPLEC algorithm is employed for pressure-velocity coupling. The Gauss-Seidel 
smoothing method is used to update values at nodal points after each iteration step. Convergence 
is controlled by setting residual tolerances of the momentum equation and the drug transport 
equations to be 1×10
-5
 and 1×10
-8
, respectively.  
In order to generate initial conditions for the transient simulation, the interstitial fluid flow 
equations are firstly solved to obtain a steady-state solution in the entire computational domain. 
Following this, the obtained pressure and velocity values are applied at time zero for the 
simulation of drug transport and cellular uptake (shown in Figure 4-2). The second order implicit 
backward Euler scheme is used for temporal discretisation, and a fixed time step size of 10 
seconds is chosen. This time step is deemed sufficiently fine based on a time step sensitivity test. 
The initial doxorubicin concentrations are assumed to be zero in both tumour and the 
surrounding normal tissue.  
Solving continuity and momentum 
equations to obtain steady-state 
solution of interstitial fluid field
Solving mass transfer equations to 
obtain time-dependent drug 
concentration and tumour cell 
denisty
IFP       IFV  
Figure 4-2. Numerical Procedures. 
There are two boundary surfaces in this model: an internal boundary between the tumour tissue 
and normal tissue, and the outer surface of the normal tissue. At the internal boundary, 
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conditions of continuity of the interstitial pressure and fluid flux are applied. At the outer surface, 
a constant relative pressure of 0 Pa and zero flux of drug are assumed.  
4.2. Results 
The analysis of results obtained from the mathematical model is carried out. The interstitial fluid 
field is firstly examined to provide the microenvironment for drug transport and cell killing. This 
is followed by comparisons of administration modes and doses under single and multiple 
administration treatments in a clinical range. Finally, computational results obtained from the 2-
D and 3-D models are compared. 
4.2.1. Interstitial Fluid Field 
The interstitial fluid field in tumour and normal tissues plays an important role in drug delivery. 
This is because on the one hand, the interstitial fluid velocity and pressure determines the drug 
migration in extracellular space by convention; on the other hand, transvascular pressure gradient 
influences the drug exchange between microvessels and the interstitial space of tumour. By 
solving Equations (3-1)~(3-8) described in Chapter 3 for a vascular pressure of 2080 Pa [49-51, 
89], the spatial distribution of interstitial fluid pressure (IFP) is presented in Figure 4-3. There is 
a uniform IFP in the tumour and normal tissue. Higher IFP is found in the tumour compared with 
its surrounding normal tissue, and there is a large gradient in a thin layer at the interface between 
the two regions. 
      
Figure 4- 3. Interstitial fluid pressure in tumour and surrounding normal tissue. 
The spatial mean IFP is 1533.88 Pa in the tumour region and 40 Pa in normal tissue. These 
results agree with experimental studies which suggested that IFP in tumour was in the range of 
586.67 Pa to 4200 Pa [48], and in normal tissue -400 Pa to 800 Pa [135]. This difference in IFP 
between tumour and normal tissue can be partially attributed to the special characteristics of 
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tumour vasculature. On the one hand, vasculature surface is enlarged because blood vessels are 
tortuous, elongated, and often dilated in tumour growth. The hydraulic conductivity is increased 
by 10-fold as a result of large pores on tumour vasculature wall [49]. This leads to a much easier 
fluid exchange across the blood vessel wall. On the other hand, the lack of lymphatic vessels 
results in less fluid being drained out of the interstitial space, causing build-up of pressure in 
tumour interstitial space. The IFP distribution shown in Figure 4-3 suggests that pressure-
induced convection of interstitial fluid mainly occurs within a thin layer at the interface between 
tumour and its surrounding normal tissue. 
In theory, high pressure in tumour poses a barrier for drug transport from blood to interstitial 
space. However, diffusion driven by concentration gradient and vasculature surface area also 
contributes to drug exchange between blood and interstitial space. Previous studies demonstrated 
that diffusion was a more important mechanism in determining drug transport across the 
vasculature wall because of the ineffective convection owing to the high IFP [51]. 
4.2.2. Single Administration Mode 
In this series of simulations, the full dose of doxorubicin is administrated at the beginning of 
each treatment. The influences of two controllable factors, infusion duration and dose level, are 
examined over a period of 9 hours following drug administration.     
4.2.2.1. Infusion Duration 
The cytotoxic effect of doxorubicin on tumour cells is evaluated for bolus injection and 
continuous infusions with different infusion durations. Given that doxorubicin is carried by the 
blood stream into the tumour and normal tissue, its concentration in blood should be examined 
when evaluating its anticancer effectiveness. The time course of doxorubicin blood concentration, 
for a total dose of 50 mg/m
2
 administered by different administration modes, is compared in 
Figure 4-4. Because all the drugs are administrated into blood stream in a very short period, 
which can be ignored in comparison with the treatment time window, drug concentration in 
blood under bolus injection reaches its peak at the very beginning of treatment. Without 
continuous supply, the concentration falls rapidly to a low level. Continuous infusion leads to 
different results. Since the total dose of drugs are administrated continuously in the infusion 
duration, drug concentration in blood increases gradually in this period. At the end of the 
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infusion duration, drug concentration begins to decrease. Therefore, the timing of peak drug 
concentration varies according to the infusion duration.  
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Figure 4-4. Doxorubicin concentration in plasma as a function of time after start of treatment, for bolus injection and 
continuous infusion of various indicated durations (dose = 50 mg/m
2
). 
Comparison of peak values in Figure 4-4 indicates that prolonging the infusion duration results 
in low peak doxorubicin blood concentration. This is because doxorubicin is being continuously 
cleared up after administration. Since high doxorubicin concentration in blood is associated with 
increased risk of cardiotoxicity, bolus injection may not be a preferred option while continuous 
infusion with longer duration may help reduce this risk. Comparison also shows that although 
fast infusion leads to higher concentrations at the beginning of the treatment, doxorubicin 
concentration in blood falls much faster after the infusion ends.  
Free and bound doxorubicin extracellular concentrations in tumour and its surrounding normal 
tissue are shown in Figure 4-5 and 4-6, respectively. Regardless of the injection mode, both free 
and bound doxorubicin concentrations increase rapidly during the initial period following drug 
administration. Doxorubicin concentrations in tumour interstitial space increase faster and reach 
a much higher peak with bolus injection. The peak value for continuous infusion decreases with 
the increase in infusion duration. Although doxorubicin concentration drops to a low level after 
infusions end for all modes of administration, continuous infusions are able to maintain a slightly 
higher concentration than bolus injection. Comparing doxorubicin extracellular concentrations in 
Figures 4-5 and 4-6 with the concentration in blood in Figure 4-4, the concentration curves have 
identical shapes for a given administration mode. This means that drug concentration in blood 
has a direct influence on the extracellular concentration for both free and bound doxorubicin.  
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Figure 4-5. Spatial mean (a) free and (b) bound doxorubicin extracellular concentration in tumour as a function of 
time under bolus injection and different infusion durations (dose = 50 mg/m
2
). 
Because binding with protein is a dynamics process, both free and bound doxorubicin 
concentrations vary with time. Comparing Figure 4-5 (a) and (b), it is clear that the time course 
of free and bound concentrations shares a similar trend, but bound doxorubicin concentration is 
approximately 3 times of the free doxorubicin concentration, indicating that most doxorubicin in 
the interstitial fluid is in bound form. Since only free form doxorubicin can be taken up by 
tumour cells [55, 90], the high binding rate is expected to reduce the intracellular concentration 
of doxorubicin.   
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Figure 4-6. Spatial mean (a) free and (b) bound doxorubicin extracellular concentration in normal tissue as a 
function of time under bolus injection and different infusion durations. (dose = 50 mg/m
2
). 
Figure 4-7 shows the spatial distribution of free doxorubicin extracellular concentration in 
tumour and its surrounding normal tissue at 0.5 hour under 2-hour continuous infusion. There is 
a difference in drug concentration between tumour and surrounding normal tissue. Since the 
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properties of doxorubicin and tissues are assumed to be uniform in each region, the 
corresponding distribution is also uniform except near the tumour boundary where a large 
concentration gradient exists. This thin layer of steep concentration gradient represents the 
exchange of drug between tumour and normal tissue.  
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Figure 4-7. Spatial distribution of extracellular concentration of free doxorubicin in tumour and normal tissues (2-
hour infusion, time = 0.5 hour). 
As has already been shown in Figure 4-3, the interstitial fluid pressure in tumour is much higher 
than in normal tissue; this pressure difference drives interstitial fluid flow from the tumour to 
normal tissue, and doxorubicin is also carried by this flux. Moreover, doxorubicin diffuses from 
tumour where its concentration is high compared to the surrounding tissue because of the large 
concentration gradient in the interstitial space. The transport from tumour to normal tissue needs 
to be minimised in order to maintain a high level of doxorubicin concentration in tumour. 
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Figure 4-8. Doxorubicin intracellular concentration as a function of time, for bolus injection and continuous 
infusions of various durations (dose = 50 mg/m
2
). 
Figure 4-8 presents the intracellular doxorubicin concentration in tumour under bolus injection 
and continuous infusions with various infusion durations. The intracellular concentration 
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displays a sharp rise at the beginning until it reaches a peak, and then decreases. During the 
initial phase, the rate of increase in doxorubicin concentration slows down with increase of 
infusion duration. Compared to continuous infusions, bolus injection leads to a higher peak and a 
faster reduction in intracellular concentration which also remains at a much lower level after 
cessation of drug administration.  
For continuous infusions, longer infusion durations tend to slow down the increase in 
intracellular concentration at the initial phase of treatment, and produce a lower peak. Here, the 
highest intracellular concentration is found for a 1-hour continuous infusion. Moreover, for 
continuous infusion with different durations, intracellular concentrations reach a very similar 
level after drug infusions terminate.  
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Figure 4-9. Predicated percentage tumour cell survival under bolus injection and continuous infusions of various 
durations (dose = 50 mg/m
2
). 
Figure 4-9 shows the percentage of survival tumour cells by applying the pharmacodynamics 
model described by Equation (3-30). As can be observed, the cytotoxic effect of bolus injection 
on tumour cells is significantly lower than that of continuous infusions. This is because of the 
rapid clearance of doxorubicin from blood (shown in Figure 4-4), resulting in a dramatic 
reduction in extracellular drug concentration which is reduced to approximately zero after 5~6 
hours (shown in Figure 4-5). Without enough doxorubicin accumulating in tumour cells, the cell 
killing rate and physical degradation rate become slower than cell proliferation rate, and hence 
tumour cell density begins to increase after reaching the minimum value at around 5 hours after 
the cessation of drug administration. On the contrary, the extracellular drug concentration with 
continuous infusion stays at a low but non-zero level for a longer period to supply sufficient 
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doxorubicin for cell killing. This is the reason for the continuous reduction in survival fraction of 
tumour cells with continuous infusion in the simulation time window.  
However, the effect of infusion duration seems to be insignificant for the limited range of 
infusion durations examined, with a difference of up to 2% between the slower (3 hours) and 
faster infusion (1 hour). The best therapeutic efficacy is not achieved with the infusion duration 
that leads to the highest intracellular concentration. Results show that 1-hour infusion leads to 
high cell killing rate at the beginning of treatment because of high intracellular concentration 
(shown in Figure 4-8). However, the killing rate slows down due to a rapid reduction in 
intracellular concentration. This low level of intracellular concentration sustains to the end of the 
simulation time window, and the therapeutic efficacy is the worst among the continuous infusion 
modes examined. On the contrary, although a 3-hour infusion results in a slower increase and 
lower peak, as shown in Figure 4-8, the intracellular concentration is at a higher level after peak 
time and the cytotoxic effect is better than others. This indicates that the final treatment outcome 
is more dependent on the intracellular concentration over the entire exposure time rather than its 
peak value. 
4.2.2.2. Effect of Dose Level 
Another controllable parameter in chemotherapy is the dose level of anticancer drugs. In current 
clinical use, doxorubicin dose ranges from 50 mg/m
2
 to 75 mg/m
2
 for a 70kg patient, hence the 
effect of dose on drug effectiveness is examined within this range. 
Comparison is made between different doses (50, 60 and 75 mg/m
2
) under a 2-hour continuous 
infusion, simulating treatment doses used for a 70 kg patient. Blood concentration of free 
doxorubicin presented in Figure 4-10 (a) shows that increasing the dose results in linear elevation 
of drug concentration. Since following the same pharmacokinetics, blood concentration of bound 
doxorubicin is believed to share the same feature. As shown in Figure 4-10 (b) and (c), 
extracellular concentration of doxorubicin in both free and bound forms are increased because of 
the close relationship between concentration in blood and in interstitial space. As a consequence, 
more drugs accumulate in tumour cells under a high dose administration.  
Results shown in Figure 4-10 (d) show that intracellular drug concentration is not proportional to 
the administrated dose level. In summary, doxorubicin concentrations in all regions increase with 
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the dose level, since a high dose increases the amount of drug delivered to both the tumour and 
normal tissues. In addition, the high concentration in blood may also increase the risk of heart 
failure.  
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Figure 4-10. Spatial mean doxorubicin concentration in tumour as a function of time under 2-hour infusion 
duration.(a) doxorubicin blood concentration, (b) free doxorubicin extracellular concentration, (c) bound 
doxorubicin extracellular concentration, and (d) intracellular concentration. 
The percentage of survival tumour cells is compared in Figure 4-11 by solving the 
pharmacodynamics equation based on the predicted intracellular concentration. The results show 
that the cytotoxic effect of doxorubicin on tumour cells increases with the dose level, with the 
difference between low (50 mg/m
2
) and high doses (75 mg/m
2
) being 2.5% at 9-hour following 
drug administration. Compared to the administrated dose level, this improvement in treatment 
outcome is not obvious.   
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Figure 4-11. Predicated percentage of tumour cell survival under various doses. 
The predicated free and bound doxorubicin concentration in the interstitial space of normal tissue 
with different drug dosages is compared in Figure 4-12. Results show that increasing the dose 
results in elevation of extracellular concentration of doxorubicin in both free and bound forms. 
This indicates that the risk of cell killing in normal tissue may also be increased at higher dose. 
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Figure 4-12. Spatial mean doxorubicin concentration in normal tissue as a function of time under 2-hour infusion 
duration (for a 70 kg patient). (a) free doxorubicin extracellular concentration, (b) bound doxorubicin extracellular 
concentration. 
4.2.3. Multiple Administration Mode 
Numerical studies are carried out under continuous infusion and bolus injection with multiple 
administrations for 2, 4 and 8 times within the first 48 hours of treatments with intervals of 24, 
12 and 6 hours, respectively. The infusion duration is set as 2-hour for each of continuous 
infusion, and the simulation is performed for 96 hours.  
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4.2.3.1. Continuous Infusion 
Figure 4-13 shows the predicted time course of plasma doxorubicin concentration, for a total 
dose of 50 mg/m
2
 administrated by single and multiple 2-hour continuous infusions. Regardless 
of the administration mode, the drug concentration in blood reaches a peak after the end of each 
administration. Results show that multiple-infusion can significantly reduce the peak plasma 
concentration, and this reduction effect increases with the number of infusion. Administrating the 
same dose of doxorubicin 8-times gives a 20% lower peak concentration compared with a single 
administration. Hence multiple-infusion is likely to reduce the risk of heart electrophysiology 
dysfunction and muscle damage caused by doxorubicin. However, quantitative comparison of 
blood concentration after administration shows that multiple-infusion can also lead to a slightly 
high level of drug concentration in plasma over time. 
 
Figure 4-13. Doxorubicin intravascular concentration under single and multiple continuous infusions as a function of 
time (total dose = 50 mg/m
2
). 
Figure 4-14 shows the time course of free and bound doxorubicin concentration in the interstitial 
fluid for different infusion modes. During each infusion period, all forms of doxorubicin begin to 
accumulate in the interstitial space since doxorubicin is continuously administrated into the 
circulation system. Drug concentration reaches a peak value at the end of each infusion, and then 
falls to a lower level as time proceeds. Results show that free and bound doxorubicin 
concentrations share the same trend for a specific administration mode. Multiple-infusion can 
effectively reduce the peak extracellular concentration and lead to a slightly higher concentration 
level over time.  
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Figure 4-14. Spatial mean doxorubicin extracellular concentration as a function of time under single and multiple 
continuous infusion. (a) free doxorubicin, and (b) bound doxorubicin (total dose = 50 mg/m
2
). 
Intracellular doxorubicin concentrations in tumour with signal and multiple-infusion modes are 
compared in Figure 4-15. It is clear that single infusion gives the highest peak intracellular 
concentration, while multiple-continuous-infusions have lower but multiple peaks which help to 
keep a sustained level of intracellular concentration over the entire treatment period.  
 
Figure 4-15. Time course of doxorubicin intracellular concentration under single and multiple continuous infusions. 
(total dose = 50 mg/m
2
) 
Figure 4-16 shows the survival fraction of tumour cells under various administration modes by 
applying the pharmacodynamics model described in Equation (3-30). As can be observed, single 
infusion is more effective at cell killing in the first 34 hours but less effective than multiple-
infusions afterwards. Comparing different fractionations under the multiple-infusion mode, cell 
killing rate is more steady and the fraction of survival tumour cells reaches a lower level as the 
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number of infusions increases. Results show that the 8-times continuous infusion can improve 
the anticancer effectiveness by 7% when compared with a single infusion.  
 
Figure 4-16. Time course of tumour survival fraction under single and multiple continuous infusions. 
(dose = 50 mg/m
2
) 
Tumour cell density is determined by the rate of cell killing, cell proliferation and degradation 
rates, hence the survival fraction may increase when intracellular concentration falls below a 
threshold value during administration intervals. By increasing administration times while 
keeping the total administration dose the same, multiple-infusion mode is effective at increasing 
doxorubicin concentrations between administration cycles (shown in Figure 4-13, 4-14 and 4-15). 
Therefore, the rate of cell death (including cell killing and degradation) is faster than that of cell 
proliferation, and as a consequence the fraction of survival tumour cells continuous to fall for a 
longer period under multiple-infusion treatments than under a single administration.  
Taking results shown in Figures 4-13, 4-14 and 4-15 together, it becomes clear that keeping 
doxorubicin at a relatively higher level for a longer period leads to a better anticancer 
effectiveness. The treatment outcome is related but not solely determined by the peak extra- and 
intra-cellular concentrations. This is because the time-scales of drug transport processes from 
blood to the interior of tumour cells are different. Although some of these time scales are 
determined by the properties of anticancer drug and tissues, the rate-limiting step is crossing the 
cell membrane [55]. The slow cellular influx requires the concentration to sustain at a high level 
for a sufficient period of time in order to let more doxorubicin accumulate in the cells. 
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Time course profiles of free and bound doxorubicin concentration in the interstitial space of 
normal tissue are presented in Figure 4-17. Results indicate that multiple-continuous-infusion 
lead to lower peak doxorubicin concentration but a slightly higher concentration level after 
administration ends. Compared with doxorubicin intravascular concentration shown in Figure 4-
13, the accumulation of doxorubicin in normal tissue is found to be strongly dependent on 
doxorubicin concentration in blood.  
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Figure 4-17. Spatial mean doxorubicin extracellular concentration in normal tissue as a function of time under single 
and multiple continuous infusion against time. (a) free doxorubicin, (b) bound doxorubicin (total dose = 50 mg/m
2
). 
Figure 4-18 compares the single infusion with a high dose and multiple-infusions with a low 
dose. In Figure 4-18 (a) and (c), intracellular concentration resulted by multiple-infusions with 
low dose is obviously low, and quantitative comparisons show that 8 times infusion with half 
dose can reduce the peak concentration by an order of magnitude  
The survival fractions of tumour cells under different administration modes are shown in Figure 
4-18 (b) and (d). Numerical results show that differences in the maximum cytotoxic effect 
between high drug dose single infusion and low drug dose 8 times infusion are 8% with a 50% 
dose and 3% with a 67% dose for multiple infusions. In addition, the recovery of tumour cells is 
slower with low dose 8 times infusion, as shown in Figure 4-18 (d). Consequently, multiple-
continuous-infusion seems to offer improved treatment outcome overall. 
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Figure 4-18. Comparison of various doses under single and multiple-infusions. (a) intracellular concentration and (b) 
cell survival fraction under single infusion with 50 mg/m
2
 and multiple infusions with 25 mg/m
2
 as a function of 
time ; (c) intracellular concentration and (d) cell survival fraction under single infusion with 75 mg/m
2
 and multiple 
infusions with 50 mg/m
2
 as a function of time. 
4.2.3.2. Bolus Injection 
The doxorubicin concentration in plasma under various bolus injection schedules are shown in 
Figure 4-19 (a). Since the injection duration is short enough to be ignored, peak blood 
concentration is reached at the beginning of each administration. Fast plasma clearance is the 
reason for the rapid fall of blood concentration after administration. Quantitative comparisons 
show that the peak intravascular concentration is inversely related to the number of injections. 
This means that multiple bolus injection can reduce the peak concentration in plasma, and hence 
may help reduce the risk of cardiotoxicity.   
The free and bound doxorubicin concentration in the interstitial space is shown in Figure 4-19 (b) 
and (c). Because doxorubicin needs to permeate through the vasculature wall and then enter the 
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interstitial space, its extracellular concentration shares a similar pattern to the intravascular 
concentration shown in Figure 4-19 (a). 
   
   
Figure 4-19. Comparison of doxorubicin concentration under single and multiple bolus injections as a function of 
time (total dose = 50 mg/m
2
). (a) intravascular concentration, (b) free doxorubicin extracellular concentration, (c) 
bound doxorubicin extracellular concentration, and (d) intracellular concentration  
The predicted time courses of doxorubicin intracellular concentration, for a total dose of 50 
mg/m
2
 administered by different bolus injection schedules, are compared in Figure 4-19 (d). 
Results show that single injection leads to the highest peak intracellular concentration, and the 
peak value decreases with the number of injections. Although sharing a similar trend to 
intravascular concentration, intracellular concentration takes longer to drop to its lowest level 
which is approximately zero. This is because the time-scale for crossing cell membrane is much 
longer than that of plasma clearance [55].  
Figure 4-20 presents the survival fraction of tumour cell based on the predicted intracellular 
concentration over time. The cytotoxic effect of single bolus injection on tumour cells is 
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significantly lower than that of multiple injections, and the difference is up to 15% between the 
single and 8-times injections.  
       
Figure 4-20. Tumour survival fraction as a function of time with single and multiple bolus injection  
(total dose = 50 mg/m
2
) 
Free and bound doxorubicin concentration in normal tissue under different bolus injection 
schedules are compared in Figure 4-21. Results show that peak concentration of doxorubicin in 
normal tissue can be reduced by increasing the number of injections.  
    
Figure 4-21. Comparison of doxorubicin concentration under single and multiple bolus injections as a function of 
time (total dose = 50 mg/m
2
). (a) free and (b) bound doxorubicin concentration in normal tissue. 
The treatment outcomes under 8-times bolus injection and a single 2-hour continuous infusion 
for the total dose of 50 mg/m
2
 non-encapsulated doxorubicin are compared in Figure 4-22. 
Although multiple injections help to improve the anticancer effectiveness as already shown in 
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Figure 4-20, results obtained with 8-times bolus injection is still not as good as that with 2-hour 
continuous infusion for the same dose. 
 
Figure 4-22. Comparison of survival fraction between single continuous infusion and 8 times bolus injection. 
(total dose = 50 mg/m
2
)  
4.2.4. Comparison of 2-D and 3-D Models 
All the simulations presented so far are based on a 2-D model reconstructed from a selected MR 
image of a transverse section. However, a real tumour and its surrounding normal tissues are 
three-dimensional (3-D). Hence, it is necessary to evaluate the need for 3D simulation by 
quantitative comparison of results based on 2-D and 3-D models. 
 
Figure 4-23. 3-D model geometry. 
For this purpose, a 3-D model is reconstructed from the same series of MR images acquired from 
a patient with prostate tumour, and a representative MR image is already shown in Figure 4-1 (a). 
The reconstructed 3-D geometry is shown in Figure 4-23, where the tumour region is highlighted 
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in orange which is surrounded by normal prostatic tissues in pale blue. The dimension of the 
reconstructed 3-D model is approximately 40 mm in length, and the tumour and normal tissue 
volumes are 2.28×10
-6
 m
3
 and 4.42×10
-5
 m
3
, respectively. The final mesh consists of 757,453 
tetrahedral elements which have been tested to produce grid independent solutions.  
Numerical simulation has been carried out for a 2-hour continuous infusion of 50 mg/m
2
 
doxorubicin. Comparisons of drug concentration and drug cytotoxic effect are summarized in 
Figure 4-24. The time courses of free doxorubicin extracellular concentration based on the 2-D 
and 3-D models are compared in Figure 4-24 (a). No difference can be observed between the two 
models. Quantitative differences in drug concentrations and tumour cell density are summarized 
in Figure 4-24 (b), which shows that differences between the 2-D and 3-D models are less than 
0.25%, justifying the use of 2-D models in this study. These results agree with the work of other 
researchers [79]. However, it is important to point out that the high level of consistence between 
the 2-D and 3-D models is mainly due to the fact that both drug and tissue properties are 
assumed to be uniform in each region. The effect of heterogeneous distribution of 
microvasculature in tumour will be addressed in Chapter 5. 
     
Figure 4-24. Comparison of drug concentration and cell density between 2-D and 3-D models. (a)  free doxorubicin 
extracellular concentration in tumour as a function of time, (b) maximum percentage differences in drug 
concentration and tumour cell density  (total dose = 50 mg/m
2
) 
4.3. Discussion 
After intravenous infusion, anticancer drugs need to experience the following steps before 
reaching the interior of tumour cells: clearance from plasma, passing through the 
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microvasculature wall, diffusion and convection in extracellular space and crossing tumour cell 
membrane. The time scale for each of these transport steps is different owing to the different 
properties of microvasculature, interstitial fluid and the kinetics of cellular uptake. Data in the 
literature suggest that there is a delay between intracellular and extracellular drug concentration 
levels [55]. This is the reason why extracellular concentration needs to be maintained at a high 
level for long enough to enable cellular uptake. Simulation results in this study show that peak 
intracellular doxorubicin concentration is achieved 0.8~19 minutes later than the corresponding 
peak extracellular concentration. Comparisons between single and multiple administration 
methods as well as dose levels suggest that a more effective administration is more successful in 
maintaining high levels of extracellular doxorubicin over longer time (shown in Figure 4-5, and 
4-10 (b,c)), and thereby raising intracellular levels (shown in Figure 4-8, and 4-10 (d)) and 
enhancing cellular uptake.   
Anticancer effectiveness is usually evaluated by cell survival fraction, which can be predicted by 
different mathematical models. As an improvement of the AUC model [104], the peak 
intracellular concentration model [55, 90] was found to have better agreement to experimental 
data. However, this model predicts the best cell kill fraction for the entire treatment only, without 
giving detailed information on the dynamic variation of tumour cell density over time. 
Knowledge of temporal variation of cell survival is important since both extra- and intra-cellular 
drug concentrations change with time during a treatment period. The pharmacodynamics model 
employed in this study overcomes this shortcoming by providing temporal profiles of cell 
survival fraction. In addition, the model allows cell proliferation and degradation to be included, 
making it a step closer to mimicking an in vivo environment. With the consideration of cell 
proliferation and degradation in the present study, results shown in Figures 4-8, 4-10, 4-14, 4-15 
and 4-16 demonstrate that sustained levels of extracellular concentration lead to higher 
intracellular concentration over time, which can cause more effective tumour cell killing.  
Comparisons of drug concentration and survival fraction of tumour cells between 2-D and 3-D 
models show that the difference between the two models is negligible. However, this verdict is 
based on a number of assumptions. Firstly, the properties of tumour and normal tissues are 
assumed to be constant. These may vary with the tissue type, growth stage and individual 
conditions of a patient. Secondly, transport properties and vascular distribution are assumed to be 
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uniform, which is not true in a real tumour. All these properties will affect the way anticancer 
drugs are transported to tumour cells, and eventually the effectiveness of anticancer treatment. 
The model parameters adopted in this study correspond to average and representative values for 
tumour and normal tissues extracted from the literature, which may be sufficient for qualitative 
study, but more information would be required for detailed quantitative analysis. 
4.4. Summary 
In this chapter, various administration modes, schedules and dose levels are compared based on a 
2-D prostate tumour model with a realistic geometry. The results show that better anticancer 
effectiveness is achieved with administration methods that are able to maintain a high level of 
extracellular concentration over the entire treatment period. 
Results on single administrations show that bolus injection is much less effective in tumour cell 
killing than continuous infusion, the latter being not only effective in improving the cytotoxic 
effect of doxorubicin on tumour cells, but also in reducing peak level of doxorubicin in blood 
stream. Modelling results also show that rapid continuous infusion leads to faster cell killing at 
the beginning of the treatment, but slow infusion modes perform better over time.  
Increasing drug doses can increase concentration levels in all regions of tumour, and improve the 
effectiveness of anticancer treatments. Whilst consideration must be given to potential side 
effects, which limit the dose used in clinical treatment, the highest tolerable dose gives the best 
result. 
Multiple-administration can improve the efficacy of anticancer treatments, while significantly 
reducing the peak intravascular concentration and therefore lower the risk of cardiotoxicity 
caused by doxorubicin in blood stream. Treatment outcomes may be improved by increasing the 
number of administrations. The simulation results indicate that reducing the total dose while 
increasing the number of continuous infusions is an effective strategy to reduce plasma drug 
concentration, hence the associated cardiotoxicity, although at the expense of a slight reduction 
in predicted anticancer effectiveness. 
  
 
 
 
 
 
 
 
5.  Effect of Tumour Properties on Drug 
Delivery 
 
The properties of tumours are decisive factors in drug transport and final treatment 
efficacy. Since in most chemotherapies anticancer drugs are carried via the systemic 
circulation, the characteristics of tumour vasculature plays a crucial role in drug 
delivery. On the one hand, vasculature in malignant tumours is highly abnormal and 
heterogeneous. A typical tumour consists of a necrotic core with no functional blood 
vessels in the centre, semi-necrotic regions with less capillaries and veins, and a 
tumour advance front which is rich in arterioles, capillaries and venules [49]. On the 
other hand, tumour vasculature density varies in the growth process, with less 
vasculature in large, advanced tumours.  
In this chapter, a liver tumour model incorporating details of microvascular 
distribution is adopted first to examine the effect of heterogeneous vasculature 
distribution on drug delivery. This is followed by studies of drug transport in prostate 
tumours with different sizes and vasculature density. 
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5.1. Heterogeneous Vasculature Distribution 
The effect of vasculature distribution is investigated in a liver tumour with anticancer drugs 
being directly administrated through intravenous infusion. The drug transport processes and their 
governing equations are consistent with those used in Chapter 4. The unique tumour geometry 
and parameters are described below. 
5.1.1. Model Geometry 
The geometry of a liver tumour is reconstructed from the post contrast MR images acquired from 
a patient using a 3.0-Tesla MR scanner (DISCOVERY MR750, GE, Schenectady, New York, 
USA). Multislice anatomical images of the liver were acquired in three orthogonal planes with 
GR sequence at three time points after systemic infusion of the tracer Gd-DTPA (gadopentetate 
dimeglumine, MW∼0.57 kDa), with each image comprising 256×256 pixels. Other imaging 
parameters are given in Table 5-1. 
Table 5-1. MR imaging parameters 
Parameter 
(unit) 
Pixel Size 
(mm) 
Field of View 
(mm) 
Slice Thickness 
(mm) 
Repetition Time 
(ms) 
Echo Time 
(ms) 
 1.3 420 5.0 3.808 1.808 
In order to build a 2D model of the tumour and its surrounding normal tissue, a representative 
transverse image is chosen, as shown in Figure 5-1 (a). The chosen section covers the maximum 
dimension of the tumour. Image processing is carried out by using Mimics (Materialise HQ, 
Leuven, Belgium), with the tumour and its sub-regions being segmented based on pixel 
intensities and contrast enhancement. It can be seen that the tumour is located at the corner with 
a maximum dimension of 41 mm and an area of 9.0×10
-4 
m
2
. The tumour is divided into 6 sub-
regions based on differences in signal intensities which are correlated to vessel densities as 
described later. Region_1 is further divided into two regions in order to compensate for any 
potential boundary effect caused by the lack of surrounding normal tissue. The resulting 
smoothed contours of the tumour and normal tissues are imported into ANSYS ICEM CFD to 
generate a computational mesh. The dimensions of the reconstructed model are approximately 
118.8 mm (maximum width) by 126.8 mm (maximum depth), and the area of the normal tissue is 
8.7×10
-3 
m
2
. The final mesh consists of 88,594 triangular elements. This is obtained based on 
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mesh sensitivity tests which are carried out until the difference in predicted drug concentration 
between the adopted mesh and a 10-time finer mesh is less than 1%.  
(a)
         
Normal Tissue
Region_3
Region_5
Region_1_1
Region_4
Region_2
Region_6
Region_1_2
(b)
 
Figure 5-1. Model geometry: (a) MR image of the liver tumour (in red) and its surrounding tissue (in pule blue); (b) 
the reconstructed 2-D geometry. 
5.1.2. Model Parameters 
A large number of model parameters are required for the computational simulation; these include 
physical and transport properties for doxorubicin, tumour and normal tissues. Essential model 
parameters adopted in the present study are summarized in Tables 3-1 and 3-3. All the geometric 
and transport parameters are considered to be independent of time, since the growth of tumour 
and its surrounding normal tissue is negligible during one simulated cycle.  
The parameter used to describe the density of vasculature is the surface area of blood vessels per 
unit volume of tumour tissue (S/V). Since Gd-DTPA is an approved contrast agent for imaging of 
blood vessels and inflamed or diseased tissue with leaky blood vessels, this MRI-visible tracer is 
first systemically administrated before MR imaging. The concentration of Gd-DTPA tracer in the 
interstitial fluid can be described by 
    GdpvGdGdpGd CFCC
V
S
P
dt
dC
__ 1                                        (5-1) 
where t is time, P is the permeability of the tracer, S/V is the surface area of blood vessels per 
unit volume of tumour tissue, CGd and Cp represent the tracer concentration in the interstitial 
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fluid and blood, respectively, Fv is the filtration rate from the blood vessels per unit volume of 
tumour tissue, and σ is the osmotic reflection coefficient of the tracer (σ = 0.6 [136]) 
The average interstitial concentration of Gd-DTPA has been found to be proportional to the 
signal relative intensity enhancement [136]: 
1100_
0_
rTS
SS
C
Gd
GdGd
Gd

                                                          (5-2) 
where SGd and SGd_0 represent the signal with and without the tracer, Gd-DTPA. T10 denotes the 
relaxation time and r1 is the relaxivity, both of which are constant and can be cancelled out 
during the evaluation of S/V. 
The spatial-mean signal intensity of each tumour region at three different time points is 
calculated, and the relative value of surface area of blood vessel per tumour size, (S/V)
*
, can be 
obtained by interpolation. The ratio of (S/V)
*
 in each tumour region to the average value for the 
entire tumour region is then used to calculate values for S/V, by scaling with the standard value 
from the literature which is 200 cm
-1
. The scaled values are summarized in Table 5-2 in 
descending order of microvasculature density.   
Table 5-2. The relative and scaled values of surface area of blood vessel per tumour size (cm
-1
) 
 Average Region_1 Region_2 Region_3 Region_4 Region_5 Region_6 
(S/V)
*
 776.52 1741.73 860.84 554.73 502.23 428.69 324.48 
S/V 200.00
**
 448.60 221.72 142.88 129.35 110.41 83.57 
** baseline value from literature [49-51] 
5.1.3. Numerical Methods 
The mathematical equations are solved by means of a finite volume based computational fluid 
dynamics (CFD) code, ANSYS FLUENT, together with tailor-made routines using the User 
Defined Scalar (UDS) function. The second order UPWIND scheme is adopted for spatial 
discretization, while temporal discretization is achieved by employing the second order implicit 
backward Euler scheme. Regarding boundary conditions, the external boundaries are the outer 
surface of the normal tissue and tumour regions_1_2, where a zero relative pressure is prescribed. 
All variables at the internal boundaries between the tumour and normal tissue and between 
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different tumour regions are assumed to be continuous. The governing equations for interstitial 
fluid flow are solved first, and the resolved pressure and velocity fields in tumour and normal 
tissues are then used to solve the mass transfer equations for drug transport. A fixed time-step of 
10 seconds is chosen following a time-step sensitivity test.  The convergence criteria for residual 
tolerances are 1×10
-5
 for momentum equations and 1×10
-8
 for mass transfer equations.  
5.1.4. Results 
A total dose of 50 mg/m
2
 non-encapsulated doxorubicin [3] is continuously infused within 2 
hours [55], simulating a typical treatment for a 70 kg patient [51]. As a foundation for drug 
delivery, the micro-mechanical environment in the tumour is examined first. This is followed by 
an analysis of the concentration profiles and drug cytotoxic effect. 
5.1.4.1. Interstitial Fluid Field 
Interstitial fluid pressure (IFP) plays an important role in determining the transport of drug in 
tumours. IFP is obtained by solving the governing equations for interstitial flow for the entire 
tumour region and its surrounding normal tissue, subject to the boundary conditions described 
above and a vascular pressure of 2080 Pa. As shown in Figure 5-2, there is no discernable 
difference among different tumour regions, although IFP in the tumour is much higher than that 
in the normal tissue. The observation that IFP is not sensitive to tumour microvasculature 
distribution is consistent with the results of Baxter and Jain [50] who found that even the 
presence of a necrotic core had virtually no effect on the IFP profile, unless the necrotic core size 
is greater than 90% of the tumour size. This is because in regions except for a thin layer close to 
the outer boundary of the tumour, IFP equilibrates with the effective vascular pressure, which is 
given by  ivpvp   ; refer to Chapter 3 for definition of symbols and parameter values. 
Based on the model parameters adopted in this study, the effective vascular pressure is 1533.88 
Pa; this is reached in all tumour regions except region_1 and region_2, where the mean IFP is 
slightly lower. This means that there is no net filtration between the microvessels and 
interstitium in regions 3~6 which are surrounded by regions 1 and 2. On the other hand, the 
rather uniform IFP in the interior of tumour implies that pressure-induced convection of 
interstitial fluid is weak there, and convective drug transport in the interstitium occurs mainly 
within a thin layer at the tumour/normal tissue interface, where there is a steep pressure gradient. 
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Figure 5-2. Interstitial fluid pressure distribution in tumour and normal tissues. 
5.1.4.2. Doxorubicin Concentration 
Figure 5-3 shows the spatial distribution of free doxorubicin at different time points in the 
tumour. It is clear that the extracellular concentration of doxorubicin is non-uniform, which is 
not surprising since the transport of drug is channelled through blood vessels, and as such, 
vasculature density is expected to have a strong influence on the spatial distribution of drug. 
Since the difference in extra- and intra-cellular concentrations between sub-regions 1_1 and 1_2 
is very small, these sub-regions are combined and referred to as region_1 in the following 
discussion.  
    
 
 
1 hour 3 hour 6 hour 12 hour 
Figure 5-3. Spatial distribution of free doxorubicin extracellular concentration in tumour regions (total dose = 50 
mg/m
2
, infusion duration = 2 hours) 
Figure 5-4 shows the variation of extracellular concentration of free and bound doxorubicin in 
the liver tumour and each of its sub-regions of different vessel densities. In all regions, the 
predicted concentration increases during the infusion period, when doxorubicin is administrated 
continuously into the circulatory system. After the end of administration, both free and bound 
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doxorubicin concentrations start falling immediately. There are obvious differences in the drug 
concentrations in the different tumour regions until at approximately 12 hours, when uniform 
doxorubicin concentrations are reached in all tumour regions (also demonstrated in Figure 5-3). 
The rate of change of doxorubicin concentration is slower in regions with low vessel density (e.g. 
region_6), owing to reduced drug exchange between plasma and interstitial fluid as a result of 
sparse vasculature. 
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Figure 5-4. Spatial mean doxorubicin extracellular concentration in tumour as a function of time. (a) Free 
doxorubicin, and (b) bound doxorubicin. (total dose = 50 mg/m
2
, infusion duration = 2 hours) 
Although vascular densities vary in the different tumour regions, the results in each tumour 
region show that nearly 75% doxorubicin is in bound form, and both free and bound drugs share 
a similar time course, confirming that the mechanism of binding with protein is independent of 
vasculature distribution.  
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Figure 5-5. Spatial mean of doxorubicin intracellular concentration in tumour regions as a function of time. (total 
dose = 50 mg/m
2
, infusion duration = 2 hours) 
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Intracellular concentration also displays a non-uniform pattern among the tumour regions of 
different vessel densities. As shown in Figure 5-5, the rate of change of intracellular 
concentration is slower and peak concentration is lower in poorly vascularised regions, similar to 
the pattern observed for extracellular concentration. This is because cellular uptake follows the 
process of transvascular transport and migration in interstitial space, therefore, the intracellular 
concentration profile is strongly dependent on the concentration in extracellular space. The 
highest peak is observed in the region with the densest microvasculature, and results in Figure 5-
5 indicate that the peak value increases monotonically with vascular density. 
5.1.4.3. Doxorubicin Cytotoxic Effect 
The predicted anticancer effectiveness, assessed based on the variation in the percentage of 
tumour cells (Figure 5-6), suggests that cell killing is more effective in well-vascularised regions 
in the first few hours, but the trend is reversed thereafter. However, the difference among the 
various regions is small, with the maximum difference being 3% between region_1 (high vessel 
density) and region_6 (low vessel density) at 12-hour following drug administration.  
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Figure 5-6. Spatial mean percentage of tumour cells in tumour regions as a function of time (total dose = 50 mg/m
2
, 
infusion duration = 2 hours). 
The spatial distributions of survival cell fraction in the tumour regions at different time points are 
shown in Figure 5-7. As a result of the non-uniform distribution of extracellular concentration 
(see Figures 5-3 and 5-4), different treatment outcomes are found in different tumour regions.  
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Figure 5-7. Spatial distribution of survival cell fraction in tumour regions.  
(total dose = 50 mg/m
2
, infusion duration = 2 hours) 
5.1.4.4. Comparison of Various Administration Schedules 
Comparisons between different doses (25, 50 and 75 mg/m
2
) for a 2-hour continuous infusion 
confirm that the qualitative trend presented above is not altered by changes in dose level. As 
shown in Figure 5-8, the maximum differences in free doxorubicin extra- and intra-cellular 
concentrations among tumour regions increase proportionally with an increase in drug dose.  
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Figure 5-8. Maximum difference among tumour regions over treatment with various doses. (a) free doxorubicin 
extracellular concentration and (b) intracellular concentration (infusion duration = 2 hours) 
Comparisons are also made between different infusion durations (1-hour, 2-hour and 4-hour) for 
a 50 mg/m
2
 continuous infusion, and the qualitative tread among tumour regions is not altered by 
this parameter. The maximum differences in free doxorubicin extra- and intra-cellular 
concentration among tumour regions, shown in Figure 5-9, indicate that prolonging the infusion 
duration may help to reduce the difference in both extra- and intra-cellular concentration among 
tumour regions.  
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Figure 5-9. Maximum difference among tumour regions over treatment with various infusion durations. (a) free 
doxorubicin extracellular concentration and (b) intracellular concentration (total dose = 50 mg/m
2
) 
5.2. Tumour Size 
The effect of tumour size is investigated using three prostate tumours under free form drug 
delivery. The drug transport processes and their governing equations are consistent with those 
adopted in Chapter 4. The unique tumour geometry and parameters are described below. 
5.2.1. Model Geometry 
Three prostate tumour models are reconstructed from images acquired from patients using a 3.0-
Tesla MR scanner (DISCOVERY MR750, GE, Schenectady, New York, USA). Multislice 
anatomical images of the prostate were acquired in three orthogonal planes with echo-planer (EP) 
sequence, with each image comprising 256 by 256 pixels. Other imaging parameters are given in 
Table 5-3.  
Table 5-3. MR imaging parameters 
   
Pixel Size 
(mm) 
Field of View 
(cm) 
Slice Thickness 
(mm) 
Repetition Time 
(ms) 
Echo Time 
(ms) 
case_1   
1.250 32.0 7.000 
3675 85.7 
case_2   4000 84.4  
case_3   4000 91.5 
An example of the MR images has been shown previously in Figure 4-1. Transverse images are 
processed using image analysis software Mimics (Materialise HQ, Leuven, Belgium), and the 
tumours are segmented from its surrounding normal tissues based on signal intensity values. The 
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resulting smoothed surfaces of the tumour and normal tissues are imported into ANSYS ICEM 
CFD to generate computational mesh for the entire volume. The dimension of the reconstructed 
models shown in Figure 5-10 is approximately 40~50 mm in length for three cases. The final 
mesh consists of 1,173,908, 1,163,374 and 1,474,027 tetrahedral elements for case 1, 2 and 3, 
respectively. These meshes have been tested to produce grid independent solutions.  
   
tumour  normal tissue 
Figure 5-10. Model geometry: (a) case_1; (b) case_2; (c) case_3 
5.2.2. Model Parameters 
Since the time window of simulations is smaller than the growth of tumour, all the geometric and 
transport parameters are considered to be independent of time. Baseline values for all model 
parameters are summarized in Tables 3-1 and 3-3. The tumour size dependent parameter is the 
surface area of blood vessels per unit volume of tumour tissue (S/V), which reflects the 
microvasculature density.   
 
Figure 5-11. Estimation of blood vessel surface area to tissue volume ratio of tumours with various tumour sizes 
(experimental data extracted from [116]). For the best fitted curve using equation y=ax
b 
(a = 54.68, b = -0.2021). 
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Pappenheimer measured S/V normal tissue and found this to be 70 cm
-1
 [117]; this value was 
adopted by Baxter and Jain [49, 50, 88] in their series of works. Hilmas and Gillette [116] 
measured this ratio in tumours with different volumes and at different growth stages by using 
morphometric methods. By using non-linear least squares curve-fitting technique, the 
relationship between S/V and tumour size is obtained (shown in Figure 5-11), and the S/V value 
for each prostate tumour is then calculated based on its own size; all the values obtained are 
summarized in Table 5-4.  
Table 5-4. Tumour size and the blood vessel surface area to tissue volume ratio in each model 
 Tumour size (mm
3
) S/V (mm
-1
) 
case_1 45.46 25.28 
case_2 2277.97 11.46 
case_3 7118.84 9.10 
 
The numerical method and boundary conditions are consistent with previous studies in this 
Chapter. 
5.2.3. Results 
A numerical simulation has been carried out for continuous infusion of 50 mg/m
2
 [3] non-
encapsulated doxorubicin in 2 hours [55], which corresponds to a standard treatment for a patient 
of 70 kg body weight [51]. The obtained interstitial fluid field is presented first as this provides 
the microenvironment for drug delivery. This is followed by comparisons of doxorubicin 
concentration in the three prostate tumours to investigate the effect of tumour size on drug 
delivery. Finally, predicted treatment outcomes based on survival fractions of tumour cells 
calculated from the pharmacodynamics model are compared.  
5.2.3.1. Interstitial Fluid Field  
Because of abnormalities in tumour, such as vasculature, cellular matrix and the components of 
interstitial fluid, tumour interstitial fluid pressure (IFP) has been found to be higher than that in 
normal tissues [49, 50, 88, 89]. Predicted IFP contours at a representative cross-section for each 
of the three tumours are shown in Figure 5-12. IFP is uniformly high in the entire tumour except 
in a thin layer close to the tumour boundary. Owing to the low pressure in normal tissue, a sharp 
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pressure gradient can be found near the boundary between tumour and the surrounding normal 
tissue.  
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Figure 5-12. Interstitial fluid pressure distribution in tumour and normal tissue 
The predicted spatial mean IFP and spatial mean transvascular flux per tumour volume in each 
tumour are shown in Figure 5-13 (a) and (b), respectively. It can be clearly observed that spatial 
mean IFP varies with tumour size, with higher IFP in larger tumour. Since  IFP in tumour centre 
are at the same for all three models (at 1533.88 Pa), the observed variation of mean IFP with 
tumour size is caused by the thin layer with a sharp IFP gradient near the tumour boundary as 
shown in Figure 5-12. It has been reported in a parameter sensitivity study that IFP gradient is 
steeper in larger tumour [49], which would result in a higher spatial mean IFP. This is consistent 
with the finding presented here.  
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Figure 5-13. The spatial mean interstitial fluid pressure and transvacular flux per tumour volume as a function of 
tumour size 
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The transvascular flux per tumour volume from blood to interstitium (Fv) is governed by 
Equation (3-2), which is recalled here: 
  ivivvv pp
V
S
KF                                            (3-2) 
As shown in Figure 5-13 (b), the spatial mean transvascular flux per tumour volume from 
vasculature is higher in small tumour. This is because: (1) the driving force is high in small 
tumour owing to the low value of spatial mean interstitial fluid pressure and uniform 
intravascular pressure; (2) higher S/V in small tumour improves this exchange. However, 
referring to the spatial distribution of IFP in Figure 5-12, the transvascular flux mainly occurs in 
the thin layer at tumour/normal tissue interface owing to the equilibrium between IFP and 
effective vascular pressure within tumour centre. Results also show that spatial mean IFP and 
transvascular flux per tumour volume are non-linearly related to tumour volume.  
5.2.3.2. Doxorubicin Concentration 
Intravascular concentrations of free and bound doxorubicin are shown in Figure 5-14. 
Doxorubicin in blood circulation system keeps increasing in the 2-hour infusion period and 
reaches the peak at the end of administration. This is followed by a rapid fall, after which there is 
a gradual and slow reduction of doxorubicin concentration as time proceeds. Quantitative 
comparison shows that 75% doxorubicin is bound with proteins in blood stream.  
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Figure 5-14. Free and bound doxorubicin concentration in blood after administration as a function of time. (infusion 
duration=2 hours, total dose=50mg/m
2
) 
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Free and bound doxorubicin extracellular concentration in tumour and its holding normal tissue 
are shown in Figure 5-15. Regardless of the tumour size, both free and bound doxorubicin 
concentrations in tumour and normal tissue increase rapidly during the initial period after 
administration, reach their peaks and then fall to a low level after the end of infusion. The rate of 
change in doxorubicin concentration slows down with the increase in tumour size. This is 
because S/V is lower in larger tumour, leading to less drug exchange between blood and tumour 
interstitium. As shown in Figure 5-15 (c) and (d), variation of tumour size has no obvious 
influence on drug concentration in normal tissue.   
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Figure 5-15. Spatial mean doxorubicin extracellular concentration as a function of time under 2-hour continuous 
infusion, dose=50mg/m
2
. (a) Free and (b) bound doxorubicin in tumour, (c) bound and (d) bound doxorubicin in 
normal tissue 
Figure 5-16 shows the amount of drug exchange between vasculature and interstitial fluid by 
convection in each tumour. Compared with the blood concentration in Figure 5-14, doxorubicin 
exchange by convection follows the same pattern. This means that blood concentration has a 
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direct influence on transvascular transport of doxorubicin by convection. Result in Figure 5-16 
also shows that transvascular transport in small tumour is higher than in large tumour.  
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Figure 5-16. Doxorubicin exchange between blood vasculature and interstitial fluid by convection as a function of 
time. (a) free and (b) doxorubicin exchange (2-hour infusion, total dose =50 mg/m
2
) 
Regardless of the tumour size, transvascular transport of doxorubicin by diffusion shown in 
Figure 5-17 experiences the following stages: (1) increasing rapidly until reaching the peak, and 
then decreasing slowly to a positive level at the end of administration; (2) dropping sharply to a 
negative level in a few minutes and then returning very slowly to zero.  
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Figure 5-17. Doxorubicin exchange between blood vasculature and interstitial fluid as a function of time in each 
tumour. (a) free and (b) bound doxorubicin exchange by diffusion owing to concentration gradient (2-hour infusion, 
total dose = 50 mg/m
2
) 
Because the initial value of doxorubicin extracellular concentration is zero, the rapid increase in 
intravascular concentration results in a large concentration gradient between blood and the 
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interstitial fluid after administration begins, therefore, transvascular transport by diffusion 
increases rapidly to its peak. Since the increase of blood concentration slows down, the gradient 
becomes small and leads to a reduction in diffusive transport. However, it is still positive until 
the end of drug administration, after which blood concentration drops rapidly and no more 
doxorubicin is supplied. As a consequence, the concentration gradient reduces to zero quickly. 
Since doxorubicin is washed out quickly, its extracellular concentration becomes higher than 
blood concentration, causing the exchange to reverse owing to a negative concentration gradient. 
Afterwards, the negative gradient becomes smaller as the extracellular concentration decreases, 
causing the diffusive transport to return to zero gradually.  
As shown in Figures 5-14 and 5-15, most of doxorubicin is in bound form in blood plasma and 
interstitial fluid. However, comparison of trans-vascular exchange of free and bound doxorubicin 
presented in Figures 5-16 and 5-17 indicates that transvascular exchange mainly depends on free 
doxorubicin. This can be attributed to the small osmotic reflection coefficient and high 
permeability of free doxorubicin, which ease the transvascular process. Results also show that 
the rate of change slows down as the tumour size increases. This is because the sparse 
microvasculature in large tumour reduces drug exchange between blood and interstitial fluid in 
tumour. 
Comparisons are made between spatial mean convection exchange and diffusion exchange by 
applying the same administration method to case_2. The result in Figure 5-18 shows that 
diffusion exchange is up to 1000 fold higher than convection during the infusion period. This 
means that diffusion dominants the drug transport process in the initial hours of anticancer 
treatment. After the end of administration, diffusive transport driven by concentration difference 
weakens but is still dominant, resulting in continued reduction in extracellular concentration. It is 
worth noting that transvascular transport by convection mainly occurs in a thin layer at the 
interface between tumour and normal tissue. On the contrary, transvascular transport by diffusion 
takes place in the entire tumour and normal tissue owing to the concentration gradient across 
microvasculature walls. 
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Figure 5-18. Comparison of (a) free and (b) bound doxorubicin exchange between blood and interstitial fluid by 
convection and diffusion in case_2 (2-hour infusion, total dose = 50mg/m
2
) 
Figure 5-19 presents the intracellular doxorubicin concentration in the tree tumours for 2-hour 
direct infusion. Given that intracellular concentration depends on the free doxorubicin 
extracellular concentration in tumour, intracellular concentration increases rapidly to its peak and 
before falling off. The computational model predicts that a small tumour with denser 
microvasculature has more rapid changing rates and higher peaks. However, intracellular 
concentration in a large tumour sustains at a slightly higher level over time.  
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Figure 5-19. Temporal profiles of predicated intracellular concentration in tumours with different sizes 
 (2-hour infusion, total dose = 50 mg/m
2
) 
5.2.3.3. Doxorubicin Cytotoxic Effect 
Figure 5-20 presents the fraction of survival tumour cells by applying the pharmacodynamics 
model described by Equation (3-30). In small tumours with a denser vasculature, more tumour 
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cells can be killed in the first few hours after administration begins. However, the drug cytotoxic 
effect in small tumours becomes worse as time proceeds. This is because the intracellular 
concentration in small tumours increases rapidly to a higher peak value, but also decreases faster 
to a low level (shown in Figure 5-19). This fast reduction leads to insufficient cell killing in the 
later hours of a treatment in small tumours. As can be observed, differences in cytotoxic 
effectiveness are limited, with a difference of up to 3.2% between case_1 (small tumour) and 
case_3 (large tumour) in the simulation duration.  
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Figure 5-20. Survival cell fraction of tumour as a function of time in three tumours with different sizes (2-hour 
infusion, total dose = 50 mg/m
2
) 
5.3. Discussion 
Results from the mathematical model show that IFP is uniform within a tumour except for the 
tumour boundary because IFP in the tumour interior reaches equilibrium with the effective 
vascular pressure, implying that there is no net filtration between the blood vessels and tumour 
interstitium. Therefore, convective transvacular transport of drug only occurs within a thin layer 
at the tumour/normal tissue interface, where there is a steep pressure gradient, and hence 
transvascular transport mainly replies on diffusion driven by concentration gradient across 
microvasculature wall.    
After administration, doxorubicin accumulates faster in tumour regions with denser vasculature 
to achieve a higher peak. This is because the rate of transvascular transport is higher than that in 
tumour regions with sparser microvasculature. Similarly, doxorubicin is rapidly drained back to 
blood lumen after the end of administrations in these regions owing to the fast plasma clearance 
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and reverse concentration gradient, resulting in a quick reduction of concentration. Similar 
results have been found when examining the effect of tumour size with different 
microvasculature density. The rate of change of concentration is faster in small tumours with 
dense microvasculature, where the anticancer efficacy is reduced.  
Results demonstrate that vasculature in tumour is a crucial factor in drug delivery. Nevertheless, 
the mathematical model employed here involves a number of assumptions. First, the tumour 
vascular network is treated as a distributed source term in the governing equations instead of 
being modelled explicitly. As a result, the effects of intravascular transport and geometric 
features of tumour vasculature are not included. While this may be an over-simplification, it is 
practical given the lack of information on realistic tumour vasculature geometry and the 
complexity in direct modelling of blood flow in a vascular network coupled with interstitial drug 
transport. Second, all the tumour regions are assumed to be perfused via microvasculature in the 
studied liver tumour model. Drug transport in tumour regions without functional blood vessels, 
such as necrotic cores, is not investigated. Third, a 2D tumour model is used instead of a full 3D 
model. Based on the comparisons between 2D and 3D models of a prostate tumour discussed in 
Chapter 4, the 3D effect on spatial-mean parameters, such as intracellular drug concentration and 
tumour cell density, is negligible. This is consistent with the work of Teo et al [79] who found 
qualitatively similar results between their 2D and 3D models of a brain tumour.  
Other assumptions include: (1) signal intensities of tracer Gd-DTPA in post-contrast MR images 
are used to calculate vascular density, with the tracer concentration in the plasma being assumed 
to be proportional to the relative change in signal intensity. This could be improved by 
measuring the intravascular concentration of Gd-DTPA directly in MR imaging [136]. (2) 
uniform transport properties and uniform tumour cell density are assumed in each tumour region. 
(3) the intratumoural formation of new blood vessels is a dynamic and complex process 
involving several cellular and subcellular events in vivo [137], and the administrated doxorubicin 
can inhibit angiogenesis rather than cytotoxic effect on tumour cells in doxorubicin-insensitive 
tumour models [138-140]. Changes in blood vessels are expected to directly affect drug 
concentration in interstitial fluid and cell killing. However, since these variations usually take 
place in days [137, 138] which are much longer than the simulated time window, the 
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vasculature-related parameters are assumed to be constant in this series of work, but their time-
varying nature needs to be considered when long simulations are carried out.   
5.4. Summary 
The effects of vasculature-related microenvironment in tumour have been investigated. 
Modelling of a liver tumour with heterogeneous vasculature distribution shows that the tumour 
interstitial fluid pressure is insensitive to the distribution of blood vessels. Even in parts of the 
tumour that is not well surrounded by holding normal tissue, the pressure gradient there is still 
limited to a thin layer with a negligible impact on the tumour interior. Better anticancer 
effectiveness is achieved in regions with low vasculature density, owing to the reduced loss of 
drugs to the plasma. 
Modelling of three prostate tumours with different sizes under direct continuous infusion 
demonstrates the nonlinear relationships between spatial-mean interstitial fluid pressure and 
tumour volume, as well as between transvascular flux per tumour volume and tumour volume. 
During the infusion period, transvascular drug exchange mainly depends on diffusion, owing to 
the concentration gradient of free drug between blood and interstitial fluid.  
  
 
 
 
 
 
 
6.  Thermo-Sensitive Liposome-Mediated 
Drug Delivery to Solid Tumour 
 
Thermo-sensitive liposome-mediated drug delivery is a promising method to reduce 
the risk of side effects in anticancer treatment. For well-designed thermo-sensitive 
liposomes (TSL) that are stable in blood, encapsulated drugs cannot be released until 
local temperature is raised above the phase transition temperature of the liposome 
membrane. Among several heating methods that are currently available, high 
intensity focused ultrasound (HIFU) is favoured for its non-invasive nature and 
accuracy when used under the guidance of MRI. In the focus region of HIFU, both 
tumour and blood are heated directly by the absorbed acoustic power, whereas 
temperature elevation in the surrounding region is achieved via heat transfer through 
convection and conduction.   
In this chapter, the acoustic model for HIFU described in Chapter 3 is firstly 
validated by comparison with experimental data. Subsequently, the coupled bioheat 
transfer and drug transport models are used to investigate TSL-mediated drug 
delivery to a realistic 2-D prostate tumour. Finally, a comparison of temperature 
profiles between 2-D and 3-D tumour models is presented. 
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6.1. Acoustic Model for High Intensity Focused Ultrasound  
Given that temperature elevation and the following drug release are consequences of absorption 
of ultrasound energy in tissue and blood, the acoustic pressure generated by HIFU is an essential 
input to the simulation of TSL-mediated drug delivery. The acoustic HIFU model described in 
Chapter 3 is applied to a standard test case for which experimental measurements are available. 
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Figure 6-1. Spatial distribution of acoustic pressure 
The test case is for a single element HIFU transducer with a 120-mm focal length and 120-mm 
aperture. The transducer with a fixed frequency of 1.33 MHz is driven by a continuous wave to 
generate 1.45 MPa at the focus point, with a corresponding intensity of 141.78 W/cm
2
. Moving 
the transducer along the beam and its orthogonal directions, the acoustic pressure in water was 
measured by a chosen 0.4 mm hydrophone in Solovchuk’s experiment [114]. The validation 
study of acoustic pressure is based on a square geometry (8cm×5.5cm) with the focus region 
located in the centre. The spatial distribution of acoustic pressure is shown in Figure 6-1. 
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Figure 6-2. Measured and computed acoustic pressure profiles at 1.33 MHz and 1.45 MPa pressure at the focal point. 
(a) along axis and (b) radial distance. Experimental data are extracted from [114]. 
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Normalized by the pressure at the focal point, acoustic pressure along the axial and radial 
distance in the focus plane is shown in Figure 6-2. Results show that the predicted acoustic 
profiles agree well with the experimental data, demonstrating the validity of the HIFU model for 
prediction of acoustic profiles in biological media [114]. 
6.2. Thermo-Sensitive Liposome-Mediated Delivery 
The combined HIFU, bioheat transfer and drug transport models are applied to a prostate tumour, 
which is heated simultaneously with the administration of TSL encapsulated doxorubicin. By 
solving the governing equations described in Chapter 3, spatial and temporal distributions of 
temperature and drug concentration in blood, tumour and normal tissues are obtained. The 
expected therapeutic efficacy is evaluated by tumour cell survival fraction. 
6.2.1. Model Description 
The mathematical model for TSL-mediated drug delivery consists of two parts: bioheat transfer 
model and drug transport model. The former covers acoustic energy generated by a single 
element ultrasound transducer, heat absorption by blood, tumour and normal tissues, as well as 
heat transfer between these compartments; while the later describes the transport of encapsulated, 
free and bound doxorubicin in blood, extracellular space of tumour and surrounding normal 
tissues, as well as cellular uptake of the drug.  
6.2.1.1. Model Geometry 
A 2-D model of prostate tumour is reconstructed from MR images; the same model has been 
used in Chapter 4.  As shown in Figure 6-3, two focus regions are chosen in order to achieve 
adequate coverage of the tumour [76, 77].  
 
Figure 6-3. Model geometry and locations of focus regions. 
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ANSYS ICEM CFD is used to generate the computational mesh. The final mesh consists of 
64,966 triangular elements. This is obtained based on mesh independence tests which show that 
the difference in predicted drug concentration between the adopted mesh and a 10 times finer 
mesh is less than 1%. 
6.2.1.2. Model Parameters 
Parameters describing the basic physical and transport properties of doxorubicin, tumour and 
normal tissue have been given in Tables 3-1, 3-2 and 3-3 in the preceding chapter. Additional 
parameters required for the acoustic and bioheat transfer models are summarised in Table 6-1. 
Since temperature elevations in response to HIFU heating may influence some of the properties 
used in the drug transport model, temperature dependence of these properties is also considered. 
Table 6-1. Acoustic and thermal properties 
Symbol Description Unit 
Value 
Source 
Blood Tumour Normal Tissue 
va ultrasound speed m/s 1540 1550 1550 [74] 
ρ density kg/m3 1060 1000 1055 [74] 
c specific heat J/kg/K 3770 3800 3600 [74] 
k thermal conductivity W/m/K 0.53 0.552 0.512 [74] 
α absorption coefficient  1.5 f 9 f 9 f [74] 
wb0 perfusion rate of blood flow at 37
oC s-1 - 0.002 0.018 [45] 
R universal gas constant J/mol/K - 8.314 8.314 [141] 
ΔE activation energy J/mol - 6.67×105 6.67×105 [141] 
Af frequency factor s
-1 - 1.98×10106 1.98×10106 [141] 
           * f represents ultrasound frequency 
HIFU Transducer  
The acoustic source is a single-element, spherically focused transducer, and its parameters are 
summarized in Table 6-2. The local acoustic intensity and peak negative pressure are set as 120 
W/cm
2
 and 1.98 MPa, respectively. 
Table 6-2. HIFU transducer parameters 
Parameter 
(unit) 
Inside diameter 
(mm) 
Outside diameter 
(mm) 
Focal length 
(mm) 
Frequency 
(MHz) 
 20.0 70.0 62.64 1.10 
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Temperature controller 
In TSL-mediated drug delivery, it is desirable to keep the tumour temperature within a narrow 
hyperthermia range which should not exceed 43
o
C to avoid vascular shut down [142]. The phase 
transition temperature of liposome strongly depends on its formulation, and a typical temperature 
is 42
o
C based on experimental studies [69, 143]. In order to achieve the target temperature range, 
a feedback system with an appropriate temperature control mechanism is required. In the present 
study, a temperature controller is incorporated, which is designed to adjust the applied ultrasound 
power according to the maximum temperature in the heated region (Tmax). The transducer power 
is determined by  
         tTTktTTktP ettciettcp maxargmaxarg    (6-1) 
where kcp and kci are Proportional-Integral (PI) control parameters, which are set as 5 and 0.006 
respectively, based on  values in the literature [72] and previous studies. 
Permeability 
(1) Free & bound doxorubicin 
Dalmark and Strom [144] measured the permeability of free doxorubicin at various temperatures, 
and found that the logarithmic value of permeability is proportional to temperature. Based on 
their data, a linear relationship was found between fold increase in logarithmic value of 
permeability and temperature, as given by Equation (6-2), and the best fitting line is shown in 
Figure 6-4. 
21log zTzP        (6-2) 
where z1 and z2 are fitted parameters which are 0.07 and 2.43, respectively. 
Hence the fold increase in permeability is 
 21110
2
1 TTz
P
P       (6-3) 
The permeability of bound doxorubicin is assumed to follow the same relation. 
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Figure 6-4. Permeability of free doxorubicin as a function of temperature. Curve fitting parameters z1=0.07 and z2=-2.43. 
Experimental data extracted from [144]. 
(2) Liposome Encapsulated Doxorubicin  
For a baseline temperature of 34
o
C, extracellular concentrations of TSL doxorubicin were found 
to have increased by 76-fold and 38-fold upon heating to 45˚C and 42˚C, respectively [145]. 
Based on these experimental data [145], a relationship between fold increase in permeability and 
temperature can be obtained by curve fitting, and the best fitting curve is given by Equation (6-4) 
and shown in Figure 6-5. 
    210120 pp mTT
21p
mTT
11p0pp ememmm

    (6-4) 
where T and T0 represent temporal temperature and body temperature, respectively, and  the 
other terms in Equation (6-4) are curve fitting parameters. 
 
Figure 6-5. Fold increase in permeability of liposome-mediated doxorubicin as a function of temperature. Curve 
fitting parameters: mp0=-10.54, To=34, mp11=5.76, mp21=5.78, mp12=5.44, and mp22=5.46. Experimental data of [145] 
are adopted. 
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Diffusivity 
According to the Stokes-Einstein equation (Equation 3-48), the fold increase in diffusivity as a 
function of temperature is  
 
1
*
2
2
*
1
2
1


T
T
D
D
             (6-5) 
where D and strands for diffusivity, and μ is the viscosity of solvent. Subscripts 1 and 2 
correspond to conditions 1 and 2, respectively. Owing to the lack of relevant data, viscosity 
values in Equation (6-5) are assumed to be those of water [146], whose dependence on 
temperature is given by Equation (6-6), with the best fitting result shown in Figure 6-6. 
 2321exp TmTmmm dddd          (6-6) 
where T is temporal temperature, and the other terms are parameters used in curve fitting. 
 
Figure 6-6. Viscosity of water as a function of temperature. Curve fitting parameter md1=5.10 md2=-0.03 
md3=1.04×10
-4
  Experimental data extracted from [146]  
Rate of Transmembrane Transport  
The transmembrane parameter was determined by El-Kareh and Secomb [55] by curve fitting to 
data obtained from in vitro experiments [101]. It has been suggested that increased cellular 
uptake of doxorubicin with heating will lead to improved outcome when the drug is 
administrated simultaneously with hyperthermia [55]. Based on data in [147], there is a 2.2-fold 
increase at 42˚C. Here, the fold increase at temperature T is obtained by linear interpolation. 
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88.724.0  Tktv                                                         (6-7) 
Perfusion rate 
Blood perfusion rate (w) also depends on temperature [141] by the following relation: 
DSww 0                                                              (6-8) 
where w0 represents the time dependent perfusion at 37˚C, and DS is the degree of vascular stasis 
with a value between 0 and 1. 
 






 
t
tRT
E
f deADS
0
*exp                                              (6-9) 
where T* is the absolute temperature as a function of time t, R is the universal gas constant, and 
Af  and ΔE represent the frequency factor and  the activation energy, respectively. 
Plasma Pharmacokinetics of Encapsulated Doxorubicin 
After intravenous administration, liposome-encapsulated doxorubicin begins to circulate to all 
over the body in circulatory system. Because of the continuous clearance in blood stream and 
drug release triggered by environmental temperature, the intravascular concentration of 
encapsulated doxorubicin (Clp) is governed by [13]:   
lprellplp
lp
CkCCL
dt
dC
                                                 (6-10) 
where CLlp and krel refer to the clearance rate and drug release rate, respectively. The initial 
concentration of encapsulated doxorubicin is 0.0191 kg/m
3
, corresponding to a total dose of 50 
mg/m
2
 in literature [62]. 
Drug Release Rate from Liposome Encapsulation 
TSL is designed to release its contents rapidly upon heating [65]. The exact release rate varies 
according to the composition of liposome, its preparation procedure and heating temperature [69]. 
The relation between percentage release and exposure time is found to follow the first-order 
kinetics expressed as [148]: 
                             tkc releRtR  1%                                                   (6-11) 
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where %R(t) is the percentage of drug released at exposure time t, Rc is the total percentage of 
drug released at a given heating temperature. This equation is used to fit experimental data 
obtained in the range of 37~42˚C [143], and curve fitting for drug release at 37 oC and 42oC is 
shown in Figure 6-7. 
    
Figure 6-7. Drug release at (a) 37
o
C and (b) 42
o
C. Experimental data extracted from [143]. 
Note that the TSL formulation used in [143] still allows some drug to be slowly released at 37
 o
C, 
although release at 42
o
C is much faster. From the best fitting results, release rates at different 
temperatures in the range of 37~42˚C are summarized in Table 6-3. Linear interpolation is 
performed to obtain release rate at temperatures between the listed temperature points, and the 
release rate is assumed to be constant when temperature exceeds 42˚C. 
Table 6-3. Release rates at various temperatures 
T (
o
C) 37 38 39 40 41 42 
krel (s
-1
) 0.00417 0.00545 0.01492 0.02815 0.04250 0.05409 
 
6.2.1.3. Numerical Methods  
The mathematical models are implemented into a finite-volume based computational fluid 
dynamics (CFD) code, ANSYS FLUENT. The User Defined Scalar (UDS) function is used to 
code bioheat transfer model, mass transfer equations governing the drug transport and 
pharmacodynamics. The momentum, drug transport and heat transfer equations are discretised 
by using the 2nd order UPWIND scheme, and the SIMPLEC algorithm is employed for pressure-
velocity coupling. The convergence is controlled by setting residual tolerances of the momentum 
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equation, drug transport equations and bioheat transfer equations to be 1×10-5, 1×10-8 and 1×10-
10, respectively. As shown in Figure 6-8, interstitial fluid equations are solved first to obtain a 
steady-state solution in the entire computational domain. The obtained pressure and velocity are 
then introduced at time zero for the simulation of bioheat transfer, drug transport and cellular 
uptake. The 2nd order implicit backward Euler scheme is employed to perform the temporal 
discretization. A fixed time step size of 0.1 second is chosen after time-step sensitivity tests. 
Solving continuity and momentum 
equations to obtain steady-state 
solution of interstitial fluid field
IFP
IFV
Solving mass 
transfer equation 
Solving acoustic equation to 
generate the acoustic pressure 
field in the whole domain
acoustic pressure
Solving bio-heat 
transfer model 
coupled
Temperature profiles
Drug concentration
Tumour Cell Density
 
Figure 6-8. Numerical Procedure 
Given the time scale of modelling is much shorter than that of tumour growth, all the boundaries 
of the tumour and normal tissue are assumed to be fixed. The interface between tumour and 
normal tissue is treated as an internal boundary, where all variables are continuous. The relative 
pressure and temperature at the surface of normal tissue is specified to be 0 Pa and 37oC, with 
zero flux of drug.  
6.2.2. Results and Discussion 
A coupled mathematical model is used to examine the interplays among the various steps 
involved in the delivery of TSL-mediated chemotherapy. Basic features of the interstitial fluid 
field are the same as those discussed in Chapters 4 and 5, which will not be repeated here. 
Results presented below are focused on spatial and temporal distributions of temperature and 
drug concentration in blood, tumour and normal tissue.  
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6.2.2.1. Temperature Profile 
For clinical application, HIFU heating for 30~60 minutes after administration of TSL are 
recommended [142]. In an experimental study [149], 10 minutes HIFU heating which was 
interleaved with a 5 minutes cooling down period was repeated 3 times. Therefore, simulations 
have been carried out for TSL-mediated drug delivery with simultaneously HIFU heating for 
durations of 10 minutes, 30 minutes and 60 minutes, respectively. Results are compared with a 
control case without heating. The two focused regions presented in Figure 6-3 are heated 
sequentially during the treatment, and the sonication duration for each region is 1 second, which 
is chosen based on previous studies. 
The time course of temperature with 10 minutes heating is shown in Figure 6-9. Variations of 
maximum and spatial-mean temperature in blood, tumour and normal tissues have a similar 
pattern in response to the heating schedule. The maximum temperature in tumour reaches the 
target value of 42oC rapidly, and is then maintained at this level owing to the temperature control 
mode governed by Equation (6-1) until the heating period ends. This is followed by a fall in 
temperature during the cooling down stage. The lower temperature in blood is because the 
continuous perfusion of blood is effective in removing heat from the focus region, and this 
forced convection via blood is the main mechanism of heat transfer in tumour and normal tissues. 
Results show that temperatures fall back to body temperature within 20 minutes after the 
cessation of heating.    
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Figure 6-9. Variations of temperature in tumour, blood and normal tissue as a function of time for 10 minutes 
heating. (a) Maximum and (b) spatial-mean temperature. 
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Since the focus regions for direct heating are located inside the tumour (shown in Figure 6-3), 
temperature in tumour increases faster and is higher than in normal tissues, whereas, temperature 
elevation in normal tissues depends on heat transfer from tumour, which in turn causes heat loss 
hence reduction in tumour temperature. However, since heat is continuously carried away by the 
circulating blood, blood temperature in the tumour region is always lower than tumour 
temperature. The large difference in spatial-mean temperature between tumour and normal 
tissues (shown in Figure 6-9 (b)) indicates that the release of doxorubicin mainly occurs in the 
tumour region, thereby achieving localised treatment and reducing the risk of side effects. Since 
blood in the tumour region is directly heated by HIFU, its mean temperature is higher than that in 
the surrounding normal tissue. 
Spatial distributions of temperature in tissues and blood at 10 minutes after heating are shown in 
Figure 6-10. It is clear that the highest temperature is located in the focus regions where tumour 
and blood are directly heated by HIFU. Temperature elevation in the surrounding regions is a 
consequence of convective and conductive heat transfer from the focus regions, and temperature 
in normal tissues is mostly around 37oC, lower than in the tumour. This temperature distribution 
can successfully enhance doxorubicin release in tumour.  
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Figure 6-10. Spatial distribution of temperature in (a) tissue and (b) blood at 10min after heating starts. 
Figure 6-10 (a) also shows that tissue temperature varies gradually from tumour to normal tissue, 
owing to similar thermal properties of tumour and normal tissues summarized in Table 6-1. The 
temperature distribution in blood shown in Figure 6-10 (b) has a similar pattern to tissue 
temperature but with a narrower range, so that the intravascular release of doxorubicin is much 
higher in HIFU focus regions than in the periphery. 
Temporal variations of temperature for 30 and 60 minutes heating are shown in Figure 6-11. 
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Identical shapes can be found in each compartment for a given heating duration. The spatial 
mean temperature of tumour tissue remains at 40oC, which is lower than the most effective 
release temperature. 
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Figure 6-11. Variations of temperature in tumour, blood and normal tissue as a function of time for various heating 
durations. (a) Maximum and (b) spatial-mean temperature for 30 minutes heating; (c) Maximum and (d) spatial-
mean temperature for 60 minutes heating. 
6.2.2.2. Drug Concentration  
Doxorubicin is initially encapsulated in TSL which are administrated intravenously and carried 
by the blood stream into the tumour and its surrounding normal tissue. The release of 
doxorubicin from TSL is triggered by elevated temperature upon HIFU heating. Therefore, the 
concentration of encapsulated and released doxorubicin in blood should be examined when 
evaluating its anticancer efficacy. The time courses of encapsulated doxorubicin intravascular 
concentration with various heating durations are compared in Figure 6-12. Because of the short 
administration period which can be ignored in comparison with the heating duration, drug 
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concentration achieves its peak at the very beginning of treatment. Owing to rapid clearance in 
the circulatory system and increased release as temperature rises, the intravascular concentration 
of encapsulated doxorubicin falls continuously until it drops to 0.  
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Figure 6-12. Spatial-mean concentration of encapsulated doxorubicin in blood stream as a function of time (dose = 
50 mg/m2). (a) in tumour, and (b) in normal tissue. 
Compared with the control case without HIFU heating, encapsulated doxorubicin concentration 
in tumour (Figure 6-12 (a)) reduces faster upon HIFU heating, owing to enhanced release rate in 
response to temperature raise. It appears that encapsulated doxorubicin concentration drops to 
almost zero after about 20 minutes, and the duration of heating (10, 30 and 60 mins) has little 
effect on encapsulated doxorubicin concentration in tumour. Since normal tissue temperature is 
approximately 2~3 degrees lower than tumour temperature during HIFU heating, the effect of 
heating on encapsulated doxorubicin concentration in normal tissue is trivial (Figure 6-12 (b)).  
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Figure 6-13. Encapsulated doxorubicin concentration in blood at 10 min after heating 
The spatial distribution  of encapsulated doxorubicin concentration in blood is shown in Figure 
6-13 at 10 minutes after heating; it clearly demonstrates that there is little encapsulated 
doxorubicin left in and around HIFU focus regions. 
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The time courses of encapsulated doxorubicin concentration in tumour extracellular space are 
presented in Figure 6-14 (a) for various heating durations. Compared with the case without 
heating, encapsulated doxorubicin accumulates faster in the extracellular space of the tumour as 
soon as HIFU heating begins. This is attributed to enhanced vascular permeability in response to 
temperature elevation. However, the peak concentration is lower and occurs earlier in treatments 
with hyperthermia. The effect of the heating duration can only be noticed after heating ends.  
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Figure 6-14. Spatial-mean concentration (a) and flux (b) of encapsulated doxorubicin in tumour extracellular space 
as a function of time. 
Encapsulated doxorubicin concentration in tumour extracellular space depends on the balance 
between the source term which accounts for drug transport from blood vessels, and the sink term 
which is related to drug release from TSL. The time courses of each term and net grain in the 60-
minute heating period are presented in Figure 6-14 (b). The source term reaches its peak very 
rapidly and then falls off as the intravascular concentration reduces. As a result of increased 
extracellular concentration and enhanced release rate, the sink term increases initially until it 
catches up with the source term at around 2 minutes after treatment begins, leading to zero 
followed by negative net gain. As a consequence, encapsulated doxorubicin extracellular 
concentration starts to fall, which in turn causes the sink term to decrease and finally reaching 
zero concentration.  
Similar patterns can be found in normal tissues as shown in Figure 6-15. Quantitative 
comparison shows that encapsulated doxorubicin concentration in normal tissues is 3 orders of 
magnitude lower than that in tumour, indicating that TSL-mediated drug delivery could 
effectively avoid liposome accumulation in normal tissue. 
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Figure 6-15. Spatial-mean concentration of encapsulated doxorubicin in extracellular space of normal tissue as a 
function of time. 
The spatial concentration of encapsulated doxorubicin in extracellular space at different time 
points is presented in Figure 6-16. Since blood vessel walls in tumour are leakier with larger 
pores than those in normal tissue [110, 150], TSL particles are designed in a size range that 
allows them to pass through the vessel walls in tumour only, thereby achieving effective 
accumulation in the extracellular space. As shown in Figure 6-16, encapsulated doxorubicin 
mainly accumulates in tumour, and drugs in normal tissue (shown in Figure 6-15) come from 
tumour by migration in the extracellular space.  
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Figure 6-16. Spatial distribution of encapsulated doxorubicin extracellular concentration in tumour and surrounding 
normal tissues at various time points with 60 minutes heating. 
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Encapsulated doxorubicin concentration in the tumour is highly heterogeneous upon HIFU 
heating. Tumour centre has lower concentration than in periphery with time proceeds, owing to 
the fast release of doxorubicin enhanced by HIFU heating in and around the focus regions. 
Because of the reduction of encapsulated doxorubicin concentration in the blood stream, the 
corresponding extracellular concentration decreases in the entire tumour and finally becomes to 
uniform at 30 minutes when the temperature falls back to 37 oC.  
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Figure 6-17. Doxorubicin extracellular concentration with various heating duration as a function of time. (a) free and 
(b) doxorubicin concentration in tumour, and (c) free and (d) doxorubicin concentration in normal tissue. 
The time courses of free and bound doxorubicin intravascular concentration in tumour and its 
surrounding normal tissue are shown in Figure 6-17. Doxorubicin is released from TSL upon 
heating, leading to an increase in intravascular concentration of drug in free and bound forms. 
However, drug concentrations fall after reaching their peaks owing to the reduction of 
encapsulated doxorubicin in blood. The predicted results show that hyperthermia is capable of 
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enhancing drug release and thereby increasing the concentration in blood in the tumour region, 
whereas heating makes little difference to intravascular concentration in normal tissue.  
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Figure 6-18. Doxorubicin extracellular concentration with various heating duration as a function of time. (a) free and 
(b) doxorubicin concentration in tumour, and (c) free and (d) doxorubicin concentration in normal tissue 
Temporal profiles of free and bound doxorubicin concentration in tumour extracellular space and 
its surrounding normal tissue are compared in Figure 6-18 between HIFU heating and no-heating. 
Regardless of the heating duration, both free and bound doxorubicin concentrations increase 
rapidly during the initial period following drug administration. Doxorubicin concentrations in 
tumour interstitial space increase faster and reach a much higher peak upon heating. Although 
doxorubicin concentration drops to a low level as time proceeds, longer heating duration is able 
to maintain a slightly higher concentration. Comparing doxorubicin extracellular concentrations 
in Figures 6-18 with the concentration in blood in Figure 6-17, the concentration curves have 
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identical shapes for a given heating duration. This means that drug concentration in blood has a 
direct influence on the extracellular concentration for both free and bound doxorubicin. 
Comparisons show that doxorubicin concentration in both free and bound forms in tumour is 
increased by up to 11.26 % upon heating, owing to enhanced drug release, whereas the influence 
of HIFU heating on doxorubicin concentration in normal tissue is trivial. On the one hand, 
encapsulated doxorubicin concentration in extracellular space of normal tissue is limited (shown 
in Figure 6-15 and 6-16), hence less free doxorubicin that can be released. On the other hand, 
although there is a large amount of encapsulated doxorubicin in blood, drug release in most 
regions of normal tissue is not enhanced as the temperature is close to 37oC.  
Spatial distributions of doxorubicin intratumoural concentration and survival fraction of tumour 
cells at 10 minutes after administration are displayed in Figure 6-19. It is clear that doxorubicin 
concentration and survival tumour cells are non-uniform, which is not surprising since the 
tumour and drug transport properties are enhanced by temperature rise, and as such, the position 
of HIFU focus regions is expected to have a strong influence on the spatial distribution of drug 
and cell killing.  
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Figure 6-19. Spatial distribution of doxorubicin concentration and cell survival fraction in tumour at 10 minutes. 
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Intracellular concentration is the highest in tumour centre where HIFU focus regions are located, 
and it decreases radially towards tumour periphery with the lowest level at the right and bottom 
corners. As a consequence, cell killing is most effective in the tumour centre, while the cytotoxic 
effect is insufficient at the right and bottom corners which are the furthest from the HIFU focus 
regions. Therefore, the heterogeneous enhancement presented in Figure 6-19 demonstrate that 
TSL-mediated drug delivery with HIFU heating is capable of improving treatment efficacy in 
designated tumour regions, and careful selection of focus regions may help achieve desired 
therapeutic effect in the entire tumour. 
Temporal profiles of intracellular concentration with various heating durations are presented in 
Figure 6-20. The intracellular concentration displays a sharp rise at the beginning until it reaches 
a peak, and then decreases. Compared with the case with no-heating, the rate of increase in 
intracellular concentration improves upon heating. Increasing heating duration results in higher 
peaks and higher intracellular concentration levels over time.  
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Figure 6-20. Doxorubicin intracellular concentration with heating and no-heating as a function of time. 
6.2.2.3. Doxorubicin Cytotoxic Effect 
The anticancer effectiveness is evaluated by calculating changes in the percentage of tumour 
cells using a pharmacodynamics model detailed in Chapter 3. As can be seen from Figure 6-21, 
the percentage of tumour cells starts to fall immediately after drug administration. There is a 
rapid cell killing phase in the first few hours after heating in all treatments, but the duration of 
this phase depends strongly on the heating duration. This is followed by a slower cell killing 
phase which lasts for approximately 2 hours (6~8 hours after administration). With further 
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reduction in the intracellular concentration, the rate of cell killing and physiological degradation 
is overtaken by that of cell proliferation, and as a result, the percentage of tumour cells begins to 
increase. Results in Figure 6-20 suggest that anticancer effectiveness can be improved by 
modifying the heating duration. 
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Figure 6-21. Survival cell fraction in treatment with various heating duration as a function of time. 
Relative to the control case with no-heating, improvement in the intracellular concentration and 
cell killing with various heating durations are compared in Figure 6-22 (a) and (b), respectively. 
Results show that improvements in intracellular concentration and cell killing are non-linearly 
related to heating duration. This may be attributed to the fast reduction of encapsulated 
doxorubicin concentration in blood and the non-linear relationship of drug transport described in 
Chapter 3. 
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Figure 6-22. Improvement by HIFU heating. (a) intracellular concentration, and (b) cell killing 
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Although simulation results presented so far demonstrate that TSL drug delivery with HIFU 
introduced hyperthermia can improve the cytotoxic effect of doxorubicin, the gain in quantitative 
terms is quite small when compared to the control case. Possible reasons are given below. 
(1) Unstable liposome. The simulated TSL formulation [143] is unstable at body temperature. 
Ideally, TSL should be designed to release its contents upon hyperthermia only, with no release 
at physiological temperature. However, this is difficult to achieve in vivo. Undesirable release at 
37 oC can reduce the intravascular concentration of encapsulated doxorubicin and thereby 
resulting in high concentration of free doxorubicin in blood. As a consequence, less doxorubicin 
can be released upon hyperthermia. High concentration of doxorubicin in blood and normal 
tissue may increase the risk of side effects, such as cardiotoxicity. Therefore, further 
improvement in liposome formulation to prevent drug release at body temperature is essential to 
future clinical application of TSL-mediated chemotherapy. 
(2) Non-optimal focus region. Tumour cell killing is mostly enhanced in HIFU focus regions.  
The rate of doxorubicin release is insufficient in the rest of the tumour as the local temperature is 
lower than 42 oC, at which drug releases is most effective. Therefore, heating strategy needs to 
be optimised in order to generate a uniform temperature profile close to the desired temperature 
within tumour; these include careful design of the number and location of focus regions, heating 
duration and HIFU scanning method.   
6.3. Comparison of 2-D and 3-D Models 
All the numerical results on TSL-mediated drug delivery presented so far are based on a 2-D 
model reconstructed from a selected MR image of a transverse section. However, a real tumour 
and its surrounding normal tissues are 3-D, and the acoustic pressure as well as the resultant 
temperature field are highly heterogeneous upon HIFU heating. Hence, it is necessary to evaluate 
the need for 3-D simulation by quantitative comparison of results based on 2-D and 3-D models. 
For this purpose, the 3-D model shown in Figure 4-23 is adopted with an improved mesh to meet 
the requirement of simulation on acoustic profiles upon HIFU heating, and the final mesh 
consists of 4,161,964 tetrahedral elements which have been tested to produce grid independent 
solutions.  
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Numerical simulation has been carried out with only one focus region located in the tumour 
centre. Comparison of the maximum temperature within the tumour is shown in Figure 6-23. No 
difference can be observed between the 2-D and 3-D models owing to the temperature control 
mode described in Equation (6-1). 
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Figure 6-23. Comparison of maximum temperature of tumour in 2-D and 3-D model. 
Temporal profiles of spatial-mean temperature of tissues and blood based on the 2-D and 3-D 
models are compared in Figure 6-24 and Figure 6-25, respectively. The predicted temperature is 
higher in 2-D model. This over-prediction is attributed to the acoustic pressure distribution which 
is highly non-uniform. The focus region to tumour size ratio is 0.17 (mm2/mm2) in the 2-D and 
0.03 (mm3/mm3) in 3-D models. Since the focus region covers more tumour regions in the 2-D 
model, the predicted temperature rises faster than in the 3-D model. Therefore, the predicted 
drug release and cell killing are expected to be more effective in 2-D model simulations.  
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Figure 6-24. Comparison of spatial mean temperature in 2-D and 3-D model. (a) tumour and  (b) normal temperature. 
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Figure 6-25. Comparison of spatial mean temperature in 2-D and 3-D model. (a) blood temperature in tumour, and 
(b) blood temperature in normal tissue. 
By incorporating bioheat transfer and drug transport in a realistic tumour model, the presents 
study has provided insights into TSL-mediated drug delivery to solid tumours. Nevertheless, the 
mathematical model employed here involves a number of assumptions.  
First, physical complexities including cavitation and the non-linear progression of ultrasound are 
ignored. It has been shown that the effects of these complexities are minor for a local intensity in 
the range of 100~1000 W/cm2 and the peak negative pressure in the range of 1~4 MPa [151, 
152]. Given that the simulated transducer parameters (acoustic intensity is 120 W/cm2, peak 
negative pressure is 1.98 MPa) are within the specified ranges, these physical complexities are 
not considered to be important at the conditions examined here.  
Second, the influence of temperature elevation on tumour properties is complicated. Hence not 
all variations, such as temperature-dependent change in plasma clearance, are included in the 
current model. Detailed descriptions and mathematical models are required in the future studies 
in order to examine these effects.  
Third, focus regions are ideally positioned in the tumour, without considering movement 
trajectory of ultrasound transducer, vascular distribution and other micro-environment in tumour. 
Moreover, only 3 heating durations have been studied. In order to have a more comprehensive 
investigation, complex heating strategies should be simulated. These include release mode, 
duration/timing of heating and various release rates.  
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6.4. Summary 
In this chapter, thermo-sensitive liposome-mediated drug delivery with various heating durations 
are compared based on a 2-D prostate tumour model with a realistic geometry. The results 
indicate that thermo-sensitive liposome-mediated drug delivery is a possible method to achieve 
localised treatment in cancer therapy. Heating duration is a controllable parameter to improve the 
efficacy of anticancer treatment. 
  
 
 
 
 
 
 
 
 
 
7.  Conclusion 
 
In this chapter, main conclusions and limitations of the present study are summarized. 
This is followed by suggestions for further works in anticancer drug delivery 
research. 
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7.1. Main Conclusion 
In this thesis, a mathematical model comprising drug transport and bioheat transfer is presented 
to simulate the delivery of anticancer drugs, either in their free form or encapsulated in thermo-
sensitive liposomes. Anticancer efficacy of the delivered drugs is predicted based on a 
pharmacodynamics model. Model parameters describing physiological and biological properties 
of tissue and drugs are derived from experimental data in the literature. The model has been 
applied to realistic tumours reconstructed from MRI in order to (a) understand the transport steps 
of non-encapsulated drugs (Chapter 4), (b) elucidate the effects of tumour properties (Chapter 5), 
and (c) examine the coupled effect of heat transfer and drug transports under thermo-sensitive 
liposome-mediated delivery (Chapter 6).    
The main findings are as follows: 
(1) Better anticancer efficacy is achieved with administration methods that are able to maintain a 
high level of extracellular concentration over the entire treatment period. 
In direct delivery of non-encapsulated drugs, continuous infusion is much more effective than 
bolus injection in improving the cytotoxic effect of doxorubicin on tumour cells and reducing 
peak levels of doxorubicin in blood stream. Although rapid continuous infusion with a high 
peak intracellular concentration leads to faster cell killing at the beginning of the treatment, 
slow infusion modes give better overall treatment efficacy.  
Increasing drug dose can increase concentration levels in the entire tumour and thereby 
improving doxorubicin cytotoxicity. Whilst consideration must be given to the limitation on 
doses used in clinical treatment owing to potential side effects, which are caused by 
doxorubicin in the circulatory system and normal tissues, the highest tolerable dose gives the 
best therapeutic efficacy. 
Multiple-administration can improve the efficacy of anticancer treatments, while significantly 
reducing the peak intravascular concentration, thereby lowering the risk of cardiotoxicity 
caused by doxorubicin in blood stream. Treatment outcomes may be improved by increasing 
the number of administrations. Although there is a slight reduction in predicted anticancer 
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effectiveness, reducing the total dose while increasing the number of continuous infusions is 
effective in reducing drug concentration in blood.  
(2) Interstitial fluid pressure is not shown to be sensitive to microvasculature density in the 
interior of tumour, implying that drug transport by pressure-induced convection is weak 
except in a thin layer close to the interface of tumour/normal tissue. However, better 
anticancer effectiveness is achieved in tumour regions with relatively low but non-zero 
microvasculature density, owing to reduced loss of drugs back to the circulatory system.  
 
(3) Spatial-mean transvascular transport is strong in small tumour which is well-vascularised, 
owing to the low spatial-mean interstitial fluid pressure and dense microvasculature. 
However, anticancer effectiveness is compromised in small tumour as a result of enhanced 
reverse diffusion of drug to the blood circulation.  
 
(4) Thermo-sensitive liposome-mediated drug delivery with hyperthermia induced by high 
intensity focused ultrasound is effective in releasing encapsulated anticancer drugs within 
targeted regions, thereby achieving localised treatment. Heating duration is an important 
factor in determining the efficacy of anticancer treatment. Increasing heating duration to 1 
hours is beneficial in help maintain higher concentration of anticancer drugs and improve 
predicted treatment efficacy.  
 
(5) Under the assumption of homogeneous and uniform tissue and drug transport properties, 2-D 
models of tumours without explicit representation of microvasculature provide comparable 
results to corresponding 3-D models as far as spatial-averaged parameters are concerned. 
Nevertheless, 3-D model is preferred for comprehensive details about spatial distributions of 
drug concentration and cell killing, especially when heterogeneous microvasculature density 
and heat transfer upon HIFU heating are considered.  
 
7.2. Limitations 
The mathematical models described in Chapter 3 involve a number of assumptions which relate 
to descriptions of tumour properties, drug transport and HIFU heating. Details of these are given 
below. 
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7.2.1. Tumour Property 
In the present study, tumour properties except for cell density are considered to be time-
independent. In reality, tumour growth is a dynamic process which requires variations of tumour 
properties with time. The effect of this assumption is considered to be minor for simulations with 
a time window of a few hours only. However, variations of tumour properties should be 
considered when simulating treatment over a very long time period.  
Except for the tumour microvasculature density studied in Chapter 5, tumour properties are 
assumed to be homogeneous. However, these properties are likely to be heterogeneous and non-
uniform, which will affect the transport of anticancer drugs to tumour cells, and eventually the 
effectiveness of an anticancer treatment.   
The present study can be regarded as a qualitative investigation for predictions of trends since all 
model parameters, apart from tumour geometry, correspond to average and representative values 
extracted from the literature. More information is required for type-specific and patient-specific 
studies.  
7.2.2. Drug Transport Model 
Tumour vascular network is treated as a source term in the governing equations instead of being 
modelled explicitly. As a consequence, the effect of intravascular transport and geometric 
features of tumour vasculature are not included. While this assumption may be an over-
simplification, it is practical given the lack of information on realistic tumour vasculature 
geometry and the complexity in direct modelling of blood flow in a vascular network coupled 
with interstitial drug transport.  
Furthermore, only the effect of intratumoural microenvironment on drug transport is considered. 
However, anticancer drugs may in turn alter the intratumoural microenvironment. For example, 
drugs such as doxorubicin also attack blood vessels [138] by reducing microvasculature density 
in tumour. This effect can be incorporated by using a more detailed description with a two-way 
interaction. 
Drug efflux from cells depends on the transmembrane protein, P-Glycoprotein (P-gp), which is 
capable of effectively reducing intracellular concentration of structurally unrelated cytotoxic 
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agents [153], such as doxorubicin [154] and cisplatin [155]. In the present study, this efflux is 
included without considering  variations of P-gp concentration over time [99]. This limitation 
can be overcome by employing an improved transmembrane model.  
7.2.3. HIFU Heating Model 
The proposed HIFU heating model is a first step towards developing a comprehensive numerical 
platform for thermo-sensitive liposome-mediated drug delivery system. The employed transducer 
only consists of one element. However, transducers with a few hundreds of elements are required 
and have been adopted in clinical use [156]. Moreover, sonication is controlled by a binary 
feedback loop with a modified algorithm [157] based on the adjustment of the ultrasound phase 
generated by each element.  
7.3. Suggestions for Future Work 
The long term goal of computational investigations of drug delivery to solid tumour is to develop 
an experiment-assisted computational modelling framework spanning across multiple spatial and 
time-scales to advance the understanding of drug transport process and provide guidance for 
improvement in anticancer treatments. Therefore, several possible modelling tasks have been 
identified and these are described below to give an overall idea about how to expand the 
modelling work described in this thesis. 
7.3.1. Realistic Blood Vessel Geometry 
The morphological feature of blood vessels in tumour is significantly different from those in 
normal tissue, leading to highly abnormal organization and connection between vessels [20, 21]. 
Experimental [158] and numerical [102] studies showed that not all the tumour cells could be 
exposed to sufficient drugs during treatment. Real micro-vasculature networks reconstructed 
from advanced imaging techniques may help to examine the effect of blood vessel geometric 
features on drug delivery and the resultant cytotoxic effect. Modelling of blood flow can then be 
coupled with intravascular drug transport. Such a model can provide spatial-temporal profiles of 
drug concentration and cytotoxic effect to gain more insights into the effect of tumour-specific 
blood vessel network on anticancer effectiveness in different types of tumours.  
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7.3.2. Nutrient Transport 
Tumour growth needs nutrient which is also carried by the circulating blood. Highly proliferating 
tumour cells and insufficient supply of nutrient, such as oxygen and glucose, may result in 
hypoxia in localised tumour regions, and cause tumour cell arrest. Given that many anticancer 
drugs (e.g. doxorubicin) act on proliferating cells because their working mechanism is to stop 
cell duplication by interacting with DNA [3], treatment efficacy may be compromised in regions 
with insufficient supply of oxygen and other nutrients. On the other hand, arrested tumour cells 
can re-proliferate after nutrition in the surrounding environment is restored, or tumour cells may 
die from nutrition shortage, resulting in the formation of necrotic core. It is important to point out 
that blood supply is closely related to the distribution of functional microvasculature. Therefore, 
it would make the model more realistic by incorporating nutrient transport, especially when 
heterogeneous distribution of microvasculature is considered. 
7.3.3. Model Validation 
The present study serves to provide predictions of qualitative trends, hence detailed model 
validations are not included except for the HIFU acoustic model. This limitation is attributed to 
both the numerical model and experiments. On the one hand, not all model parameters are 
available for a specified tumour, especially when considering the unique condition of each 
patient; on the other hand, important results, such as intracellular concentration and cell density, 
cannot be directly measured in vivo. Animal experiments may help to provide comparable data 
for validation. Advanced optical methods, such as high-performance liquid chromatography, can 
potentially be used to obtain in vivo data for validations in the future. 
7.3.4. Type / Patient-Specific Tumour 
The properties of tumour and normal tissue vary with tissue type, growth stage and individual 
conditions of a patient [41, 45]. These variations may influence drug transport processes and 
eventually the anticancer efficacy. Numerical study can be used to predict these differences and 
provide suggestions in order to optimize treatments. However, detailed type-specific and patient-
specific information is required. 
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7.3.5. Chemotherapy Drugs 
Since different anticancer drugs can be combined in clinical use [3, 159, 160], it would be useful 
to simulate drug transport and cell killing for different combinations of drugs. Most of 
chemotherapy drugs experience similar transport processes in delivery to tumour cells, including: 
transport within/through blood vessels, migration in interstitial space and cell uptake. Besides 
doxorubicin, the basic mathematical model presented here can be applied to various drugs, such 
as 5-fluorouracid, BCNU, cisplatin, Methotrexate and antibody (e.g. Fab and IgG). Necessary 
modifications should be made in terms of drug-specific properties and behaviour. For instance, 
5-fluorouracid and cisplatin do not easily bind with proteins [17]. 
7.3.6. HIFU Heating Strategy 
Heating strategy is essential in thermo-sensitive liposome-mediated drug delivery systems. 
Further computational studies should be carried out to design an optimal heating strategy that 
aims to generate a uniform temperature distribution within designated tumour regions in order to 
improve local treatment efficacy while reducing side effects to normal organs. HIFU scanning 
method of multiple-element transducer can be designed to maintain tumour temperature above 
the phase transition temperature of liposome while minimising heating of untargeted regions. 
Moreover, the predicted anticancer efficacy can be influenced by a number of factors which 
should be optimised for the treatment of different types of tumours; these include release mode 
(intra- and extra-vascular triggered release), duration and timing of heating and release rate of 
chemotherapy drugs.  
In summary, a mathematical model for drug delivery in free and encapsulated forms has been 
developed in order to provide qualitative and mechanistic understanding of anticancer drug 
transport and cytotoxicity in solid tumours. The developed numerical platform can serve as a 
foundation for further comprehensive investigations on anticancer drug delivery. 
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Appendix:  Nomenclature 
Symbols 
A1 parameter of pharmacokinetic model for doxorubicin 
A2 parameter of pharmacokinetic model for doxorubicin 
A3 parameter of pharmacokinetic model for doxorubicin 
Af frequency factor 
b chord from the ultrasound transducer centre to the radiator boundary 
c  specific heat  
Cbe bound doxorubicin concentration in interstitial fluid 
Cbp bound doxorubicin concentration in blood plasma  
Cfe Free doxorubicin concentration in the interstitial fluid  
Cfp free doxorubicin concentration in blood plasma  
CGd  tracer concentration in the interstitial fluid 
Ci intracellular doxorubicin concentration 
CLbp plasma clearance of bound doxorubicin 
Cle liposome encapsulated drug concentration in the interstitial fluid  
CLfp plasma clearance of free doxorubicin 
Cp_Gd  tracer concentration in blood 
Cv doxorubicin concentration in blood plasma  
d distance from a point on the radiator to a field point 
Dbe diffusion coefficient of the bound doxorubicin-protein 
Dc tumour cell density  
Dd drug dose  
Dfe diffusion coefficient of free doxorubicin 
Dl  diffusion coefficient of liposomes 
DS degree of vascular stasis  
DW diffusion coefficient in water 
EC50  drug concentration producing 50% of fmax 
Fbe bound doxorubic gain  from blood vessels 
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Ffl doxorubicin loss of doxorubicin to the lymphatic vessels per unit volume of tissue 
Ffp doxorubicin gained from the blood capillaries in tumour and normal tissues 
Ffp free doxorubicin gained from the capillaries in tumour and normal tissues 
Fll loss of liposomes through the lymphatic vessels per unit volume of tissue 
Flp liposomes gained from the capillaries in tumour and normal tissues 
Fly interstitial fluid absorption rate by the lymphatics per unit volume of tumour tissue 
fmax  cell-kill rate constant  
Fv interstitial fluid loss from blood vessels per unit volume of tumour tissue 
h depth of the concave surface  
Ia ultraound intensity 
k thermal conductivity 
ka doxorubicin-protein binding rate 
kac acoustic velocity potential 
kB Boltzmann's constant 
kci PI control parameter 
kcp PI control parameter 
kd doxorubicin-protein dissociation rate 
ke michaelis constant for transmembrane transport 
kg  cell physiological degradation rate 
ki michaelis constant for transmembrane transport 
Kly hydraulic conductivity of the lymphatic wall 
kp cell proliferation rate constant 
krel  release rate of doxorubicin from liposome 
Kv hydraulic conductivity of the microvascular wall 
md inceased fold of diffusivity 
mp inceased fold of permeability 
mtv inceased fold of transmembrane rate 
MW molecular weight  
P permeability 
pa acoustic pressure  
Pbe permeability of vessel wall to bound doxorubicin 
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Pef trans-capillary Peclet number  
Pfe permeability of vasculature wall to free doxorubicin 
pi  interstitial fluid pressures 
ply intra-lymphatic pressure 
pv  vascular pressures 
q ultrasound power deposition 
r radius of spherical particle 
R universal gas constant 
s  percentage of bound doxorubicin 
S/V  surface area of blood vessels per unit volume of tumour tissue 
(S/V)
*
  relative value of surface area of blood vessel per tumour size 
Sb net rate of doxorubicin gained from association/dissociation with bound doxorubicin-
protein  
SGd  MRI signal with tracer 
SGd_0  MRI signal without tracer 
Si net rate of doxorubicin gained from the surrounding environment 
Sl net rate of liposomes gained from the surrounding environment 
Slp liposomes gained from plasma 
Sly/V  surface area of lymphatic vessels per unit volume of tumour tissue 
Sr released drug in the interstitial fluid 
Su influx/efflux from tumour cells 
Sv net rate of doxorubicin gained from the blood/lymphatic vessels 
T temperature 
T* absolute temperature 
T0 body temperature 
t time 
td  infusion duration 
Tn normal body temperature 
u0 velocity constant  
va speed of ultrasound 
VB plasma volume 
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Vmax rate of trans-membrane transport 
VT  tumour volume 
W diagonal matrix  
w perfusion rate of blood flow 
w0 perfusion rate of blood flow at body temperature 
ΔE activation energy  
 
Tensor 
C matrix of the inertial loss term 
F Darcian resistance to fluid flow through porous media  
I unit tensor 
u normal velocity of a slightly curved radiating surface 
v velocity of the interstitial fluid 
 
Greek Letter 
α ultrasound absorption coefficient 
α1 compartment clearance rate of doxorubicin 
α2 compartment clearance rate of doxorubicin 
α3 compartment clearance rate of doxorubicin 
ɛ cellular efflux function 
ζ cellular uptake function 
κ permeability of the interstitial space 
λ wave length of ultrasound 
μ dynamic viscosity of interstitial fluid  
πi osmotic pressure of interstitial fluid 
πv  osmotic pressure of the plasma 
ρ density 
σ osmotic reflection coefficient  
σd osmotic reflection coefficient for the drug molecules 
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σT average osmotic reflection coefficient for plasma protein 
τ  stress tensor  
φ  tumour fraction extracellular space 
Ψ acoustic velocity potential 
ω angular frequency of ultrasound transducer 
 
Abbreviation 
BSA body surface area 
BSNC bis-chloroethylnitrosourea 
CFD computational fluid dynamics 
FVM finite volume method 
Gd-DTPA gadopentetate dimeglumine 
HIFU high intensity focused ultrasound  
IFP interstitial fluid pressure 
IFV interstitial fluid velocity 
MRI magnetic resonance image  
MW molecular weight 
PEG polyethylene glycol  
PDT photodynamic therapy  
P-gp P-Glycoprotein 
TSL thermo-sensitive liposome 
UDS user defined scalar 
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